

Handbook of
**TOXICOLOGY OF
CHEMICAL WARFARE
AGENTS**

Edited by Ramesh C. Gupta

Third Edition



Handbook of Toxicology of Chemical Warfare Agents

THE UNCERTAINTY OF THE DANGER BELONGS
TO THE ESSENCE OF TERRORISM

Jurgen Habermas (1929–Present)

Handbook of Toxicology of Chemical Warfare Agents

Third Edition

Edited by

Ramesh C. Gupta, DVM, MVSc, PHD, DABT, FACT, FACN, FATS

Professor and Head, Toxicology Department, Breathitt Veterinary Center,
Murray State University, Hopkinsville, KY, United States



ACADEMIC PRESS

An imprint of Elsevier

Academic Press is an imprint of Elsevier
125 London Wall, London EC2Y 5AS, United Kingdom
525 B Street, Suite 1650, San Diego, CA 92101, United States
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom

Copyright © 2020 Elsevier Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library

Library of Congress Cataloguing-in-Publication Data

A catalog record for this book is available from the Library of Congress

ISBN: 978-0-12-819090-6

For Information on all Academic Press publications
visit our website at <https://www.elsevier.com/books-and-journals>

Publisher: Andre Gerhard Wolff
Acquisitions Editor: Kattie Washington
Senior Editorial Project Manager: Kristi Anderson
Senior Production Project Manager: Kiruthika Govindaraju
Cover Designer: Christian Billow

Typeset by MPS Limited, Chennai, India



Dedication

This book is dedicated to my beloved wife Denise, daughter Rekha, and parents, the late Chandra and Triveni Gupta.

Contents

List of contributors	xxvii		
Introduction	xxxiii		
Section I			
Historical perspective and epidemiology	1		
1. History of toxicology: from killers to healers	3		
<i>Eugenie Nepovimova and Kamil Kuca</i>			
1.1 Introduction	3		
1.2 Ancient times	3		
1.3 The Middle Ages	5		
1.4 The modern era	11		
1.5 Concluding remarks and future directions	13		
Acknowledgment	14		
References	14		
2. Historical perspective of chemical warfare agents	17		
<i>Nathan H. Johnson, Joseph C. Larsen and Edward C. Meek</i>			
2.1 Introduction	17		
2.2 The first sustained use of chemicals as agents of war	18		
2.3 Initial countermeasures	19		
2.4 Events after World War I	20		
2.5 World War II	21		
2.6 Post–World War II	22		
2.7 Incapacitants and toxins	23		
2.8 Recent experience	24		
2.9 Terrorist use	25		
2.10 Concluding remarks and future directions	25		
References	25		
3. Global impact of chemical warfare agents used before and after 1945		27	
<i>Jiri Bajgar, Josef Fusek, Jiri Kassa, Kamil Kuca and Daniel Jun</i>			
3.1 Introduction		27	
3.2 Background		27	
3.3 Military use of chemical weapons		29	
3.4 The period between World War I and World War II		30	
3.5 World War II		30	
3.6 The period after World War II, and the Cold War		30	
3.7 Iraq–Iran War and the Afghanistan War		31	
3.8 Vietnam War		32	
3.9 Development of VX agent		32	
3.10 Persian Gulf War		32	
3.11 Syria		33	
3.12 Unintentional use of toxic chemicals		33	
3.13 Terrorist use of chemical weapons		33	
3.14 Negotiations		34	
3.15 Concluding remarks and future directions		35	
Acknowledgment		35	
References		35	
4. Sarin attacks in Japan: acute and delayed health effects in survivors		37	
4.1 Part 1 Sarin attacks in Japan: acute and delayed health effects in survivors of the Matsumoto incident			
<i>Tamie Nakajima</i>			
4.1.1 Introduction		37	
4.1.2 Matsumoto sarin incident		37	
4.1.3 Acute impacts		38	
4.1.4 Long-lasting complaints		38	
4.1.5 Psychological impacts		40	
4.1.6 Ten years after the sarin incident		40	
4.1.7 Conclusion		42	
References		43	

4.2	Part 2 Tokyo sarin attack: acute health effects				
	<i>Tetsu Okumura, Toshiharu Yoshioka, Takemi Yoshida, Yukio Kuroiwa and Tetsuo Satoh</i>				
4.2.1	Overview of the Tokyo subway sarin attack	43			
4.2.2	Emergency treatment of sarin toxicity	44			
4.2.3	Laboratory findings in sarin toxicity	47			
	Acknowledgments	47			
	References	47			
4.3	Part 3 Structural changes in the human brain related to sarin exposure				
	<i>Hidenori Yamasue</i>				
	Acknowledgments	52			
	References	52			
5.	Early and delayed effects of sulfur mustard in Iranian veterans after the Iraq–Iran conflict	55			
	<i>Mahdi Balali-Mood</i>				
5.1	Introduction	55			
5.1.1	Brief chemistry	55			
5.1.2	Summarized historical uses	55			
5.2	Types and routes of exposure	55			
5.3	Human toxicity	56			
5.4	Main mechanisms of toxicity	56			
5.5	Target organs and acute clinical features	56			
5.6	Hematoimmunological complications	58			
5.7	Delayed clinical complications	58			
5.8	Respiratory tract	59			
5.8.1	Chronic bronchitis	60			
5.8.2	Asthma	60			
5.8.3	Bronchiectasis	60			
5.8.4	Large airway narrowing	60			
5.8.5	Pulmonary fibrosis	60			
5.9	Peripheral neuromuscular complications	61			
5.10	Dermal delayed effects	61			
5.11	Ophthalmologic complications	61			
5.12	Psychiatric complications	62			
5.13	Carcinogenicity	62			
5.14	Reproductive complications	62			
5.15	Cardiovascular complications	62			
5.16	Recent advances in sulfur mustard poisoning and its complications	62			
5.17	Concluding remarks and future directions	63			
	References	63			
6.	Epidemiology of chemical warfare agents	67			
	<i>Linda A. McCauley</i>				
6.1	Introduction	67			
6.2	Pre-World War II	67			
6.3	World War II	67			
6.4	Post-World War II	68			
6.5	Iran–Iraq War	70			
6.6	1991 Gulf War	71			
6.7	Syrian War	73			
6.8	Terrorism	74			
6.9	Concluding remarks and future directions	75			
	References	75			
7.	Chemical weapons of mass destruction and terrorism: a threat analysis	79			
	<i>René Pita, Arturo Anadón, Alejandro Romero and Kamil Kuca</i>				
7.1	Introduction	79			
7.2	Chemical weapons for terrorist actions	79			
7.2.1	“Classical” chemical warfare agents: vesicants and nerve agents	79			
7.2.2	Incapacitating agents	80			
7.2.3	Riot control agents	80			
7.2.4	Toxic industrial chemicals	81			
7.2.5	Toxins	81			
7.3	Tampering with chemical weapons	81			
7.4	State terrorism	82			
7.5	Nationalist and separatist terrorist groups	83			
7.6	Left-wing terrorist groups	83			
7.7	Right-wing terrorist groups and lone actors	84			
7.8	Apocalyptic cults: Aum Shinrikyo	84			
7.9	Jihadist terrorism: Al Qaeda, Daesh, and the Global Jihad Movement	85			
7.9.1	Weapons of mass destruction intentions	85			
7.9.2	Chemical weapon capabilities	86			
7.9.3	Plots with chemical weapons	88			
7.10	Concluding remarks and future directions	91			
	References	92			

Section II

Agents that can be used as weapons of mass destruction 95

8. Organophosphate nerve agents 97

Robert A. Young and Annetta Watson

8.1 Introduction 97

8.2 Background 98

8.2.1 Development of organophosphate formulations as chemical warfare agents 98

8.2.2 Destruction of nerve agent stockpiles 98

8.2.3 Physical and chemical properties of nerve agents 98

8.2.4 Mode of action and clinical signs 101

8.2.5 Direct nervous system effects 101

8.2.6 Binding with blood cholinesterases 102

8.2.7 Binding with other enzymes 102

8.3 Toxicity 104

8.3.1 Effects 104

8.3.2 Minimal potential for delayed neuropathy 104

8.3.3 Long-term effects following exposure to nerve agents 105

8.3.4 Evaluation of other potential effects 105

8.3.5 Inhalation/ocular toxicity in controlled experiments with human subjects 105

8.3.6 Inhalation/ocular toxicity in laboratory species 107

8.4 Risk assessment 112

8.4.1 Acute exposure guideline levels 112

8.4.2 Estimated oral reference doses 114

8.4.3 Management of exposure to nerve agents 115

8.4.4 Critical role of decontamination 115

8.4.5 Signs and symptoms guiding medical management 115

8.4.6 Nerve agent antidotes 115

8.4.7 Ongoing antidote development 116

8.5 Concluding remarks and future directions 118

Acknowledgments 118

References 118

9. Russian VX 127

Vladimir Rembovskiy, Elena Savelieva, Andrey Radilov, Natalia Samchenko, Georgy Karakashev, Mikhail Leninskiy, Nadezhda Koryagina, Sergey Kuznetsov, Igor Mindukshev, Natalia Khlebnikova, Richard Jenkins and Nikolay Goncharov

9.1 Introduction and background 127

9.2 Monitoring of Russian VX 128

9.2.1 Ambient monitoring of Russian VX 128

9.2.2 Biomonitoring of Russian VX 130

9.3 Mechanisms of action and principles of therapy 133

9.3.1 Acute intoxication with Russian VX 133

9.3.2 Delayed effects: chronic and subchronic intoxication with Russian VX 134

9.3.3 Delayed effects: embryo- and gonadotoxicity, mutagenesis, and carcinogenesis 135

9.3.4 Principles of therapy 136

9.4 Toxicometry and hygienic regulations 136

9.5 Concluding remarks and future research 138

References 139

10. Novichoks 143

Eugenie Nepovimova and Kamil Kuca

10.1 Historical overview 143

10.2 Synthesis 145

10.3 Physicochemical properties 145

10.4 Mechanism of action 146

10.5 Toxicity 147

10.6 Concluding remarks and future directions 148

Acknowledgment 148

References 148

11. Blister agents 149

Robert A. Young and Cheryl B. Bast

11.1 Introduction 149

11.1.1 Sulfur mustards 150

11.1.2 Nitrogen mustards 150

11.1.3 Lewisite 152

11.2 History and background 153

11.2.1 Sulfur mustards 153

11.2.2 Nitrogen mustards 153

11.2.3 Lewisite 154

11.3 Toxicokinetics 154

11.3.1 Sulfur mustards 154

11.3.2 Nitrogen mustards 155

11.3.3 Lewisite 155

11.4 Mode of action 155

11.4.1 Sulfur mustards 155

11.4.2 Nitrogen mustards 156

11.4.3 Lewisite 156

11.5 Toxicity 156

11.5.1 Sulfur mustard 156

11.5.2 Nitrogen mustards 159

11.5.3 Lewisite 160

11.6	Risk assessment	161	12.9	Concluding remarks and future directions	190
11.6.1	Sulfur mustards	161		References	190
11.6.2	Nitrogen mustards	163	13. Phosgene oxime		197
11.6.3	Lewisite	163		<i>Neera Tewari-Singh</i>	
11.7	Treatment	163	13.1	Introduction	197
11.7.1	Sulfur mustards	163	13.2	Properties and chemistry	197
11.7.2	Nitrogen mustards	164	13.3	Exposure and toxicity	198
11.7.3	Lewisite	164	13.4	Mechanism of action	199
11.8	Concluding remarks and future directions	165	13.5	Protection, decontamination, and treatment	200
	References	165	13.6	Concluding remarks and future directions	200
12. Riot control agents		171		Acknowledgment	201
	<i>Jaroslav Pejchal</i>			References	201
12.1	Introduction	171	14. Psychotomimetic agent BZ (3-quinuclidinyl benzilate)		203
12.2	History	171		<i>Josef Fusek, Alzbeta Dlabkova and Jan Misik</i>	
12.3	Background	173	14.1	Introduction	203
12.3.1	The agents and their physicochemical properties	173	14.2	Background	204
12.4	Mechanism of action	178	14.3	Toxicokinetics and mechanism of action	205
12.5	Toxicokinetics	179	14.4	Toxicity	206
12.5.1	Uptake, distribution, and metabolism of ortho-chlorobenzylidene malononitrile	179	14.5	Symptoms	207
12.5.2	Uptake, distribution, and metabolism of dibenz(<i>b,f</i>)-1:4-oxazepine	179	14.6	Risk assessment	207
12.5.3	Uptake, distribution, and metabolism of capsaicin	180	14.7	Treatment	207
12.6	Toxicity	180	14.8	Analytical methods	210
12.6.1	Ophthalmological effects	181	14.9	Agent BZ in behavioral research	210
12.6.2	Nasal/pharyngeal toxicity	183	14.10	Concluding remarks and future directions	211
12.6.3	Cardiovascular toxicity	183		References	212
12.6.4	Respiratory toxicity	184	15. Fluoroacetate		215
12.6.5	Neurologic toxicity	185		<i>Nikolay Goncharov, Elena Savelieva, Nadezhda Koryagina, Valeriy Zinchenko, Sergey Kuznetsov, Igor Mindukshev, Pavel Avdonin, Anton Ukolov and Richard Jenkins</i>	
12.6.6	Gastrointestinal toxicity	186	15.1	Introduction	215
12.6.7	Dermatological toxicity	186	15.2	Background	215
12.6.8	Other toxicity	187	15.3	Toxicokinetics	216
12.6.9	Lethality	188	15.3.1	Detoxification	216
12.6.10	Traumatic injuries	188	15.3.2	Analytical procedure	216
12.7	Risk assessment	188	15.3.3	Distribution in tissues and elimination	217
12.7.1	Identification of intended and unintended effects	188	15.4	Mechanism of action	217
12.7.2	Dose response	188	15.4.1	Molecular mechanism of aconitase inhibition	217
12.7.3	Exposure assessment	189			
12.7.4	Characterization of the risk and risk management	189			
12.8	Treatment	189			
12.8.1	Eyes	189			
12.8.2	Skin	189			
12.8.3	Respiratory	190			

15.4.2	Physiological and biochemical effects of fluoroacetate	218	17.4.1	Absorption, metabolism, and excretion in laboratory animals and humans	254
15.4.3	Physiology of blood vessels under intoxication with fluoroacetate	224	17.5	Mechanism of action	255
15.4.4	Body temperature of rats and rabbits under intoxication with fluoroacetate	224	17.6	Toxicity	255
15.4.5	Electrophysiological studies of fluoroacetate intoxication	225	17.6.1	Clinical effects: signs and symptoms	255
15.5	Toxicity and risk assessment	225	17.7	General treatment recommendations	257
15.6	Treatment	230	17.7.1	Referral to healthcare facilities	257
15.7	Concluding remarks and future directions	232	17.7.2	Home observation criteria	257
References		233	17.7.3	Treatment at healthcare facilities	258
			17.8	Concluding remarks and future directions	259
			References		260
16. Strychnine		239	18. PCBs, dioxins, and furans: human exposure and health effects		267
<i>Jiri Patocka</i>			<i>Bommanna G. Loganathan and Shigeki Masunaga</i>		
16.1	Introduction	239	18.1	Introduction	267
16.2	Background	239	18.2	Historical background	267
16.2.1	Chemistry and physicochemical properties	239	18.3	Human exposure to PCBs, PCDDs, and PCDFs	269
16.2.2	History	239	18.4	Physicochemical properties and global distribution	270
16.2.3	Therapeutic uses	240	18.5	Analytical methods	272
16.3	Pharmacokinetics and toxicokinetics	240	18.6	Mechanism of action and toxicity	274
16.3.1	Absorption, distribution, metabolism, and excretion	240	18.7	Concluding remarks and future directions	275
16.4	Clinical symptomatology	241	References		275
16.5	Mechanism of action	241	19. Polycyclic aromatic hydrocarbons: implications for developmental, molecular, and behavioral neurotoxicity		279
16.6	Toxicity	242	<i>Claire E. Bollinger, Monique McCallister, Ryan Clark, Raina Rhoades, Mark Maguire, Russell E. Savage, Yuqin Jiao, Kenneth J. Harris, Aramandla Ramesh, Heather Lochotzki and Darryl B. Hood</i>		
16.6.1	Animal toxicity	242	19.1	Introduction	279
16.6.2	Human toxicity	242	19.2	Background	279
16.6.3	Diagnosis	244	19.2.1	Epidemiological evidence for the negative effects of PAHs on pregnant women	279
16.7	Risk assessment	244	19.2.2	Conclusion from prospective epidemiology cohort studies	280
16.7.1	Human health hazard	244	19.2.3	Effects of maternal stress	280
16.7.2	Safety data	244	19.2.4	PAH-DNA adducts	282
16.8	Treatment	245			
16.9	Concluding remarks and future directions	245			
References		245			
17. Superwarfarins		249			
<i>Michael J. Murphy</i>					
17.1	Introduction	249			
17.2	Background	249			
17.2.1	AAPCC data on superwarfarins	251			
17.3	Classification of superwarfarins	251			
17.3.1	4-Hydroxycoumarins	251			
17.3.2	Indanediones	254			
17.4	Toxicokinetics	254			

19.2.5	Refinement of our susceptibility-exposure paradigm to assess the effects of in utero exposure to PAH aerosols on neurodevelopmental processes	283	21.3	Arsine	304
19.2.6	Refinement of our susceptibility-exposure paradigm to assess the effects of in utero exposure to PAH aerosols on behavioral phenotypes	283	21.3.1	Synthesis of arsine	305
19.3	PAH experimental model systems	284	21.3.2	Metabolism of arsine	305
19.3.1	Toxicological observations from modeling B(a)P aerosols	284	21.3.3	Mechanism of toxicity	305
19.3.2	In situ generation of “oxidative metabolites” in neocortical tissue from in utero exposure to B(a)P aerosol	284	21.3.4	Effects on humans	305
19.3.3	Temporal modulation of NMDA-mediated developmental processes as a result of in utero exposure to B(a)P aerosol	286	21.3.5	Diagnostic tests	306
19.3.4	Rescue of spatial discrimination deficit phenotypes in brain- <i>Cpr</i> -null offspring subsequent to in utero exposure to B(a)P aerosol	287	21.4	Organic arsenicals	306
19.4	Implications	288	21.4.1	Mechanism of toxicity	306
19.5	Other model systems used for PAH-induced neurotoxicity and role of the microbiome	294	21.4.2	Symptoms	307
19.6	Concluding remarks and future directions	295	21.5	Methyldichloroarsine	307
References		295	21.6	Dlphenylchloroarsine	307
20. Thallium	299		21.6.1	Structure	307
<i>Larry J. Thompson</i>			21.6.2	Effects of dlphenylchloroarsine	307
20.1	Introduction	299	21.7	Ethyldichloroarsine	307
20.2	Background	299	21.7.1	Structure	308
20.3	Toxicokinetics	300	21.7.2	Effects of ethyldichloroarsine	308
20.4	Mechanism of action	300	21.8	Lewisite	308
20.5	Toxicity	300	21.8.1	Background	308
20.6	Risk assessment	300	21.8.2	Mechanism of action and toxicokinetics	308
20.7	Treatment	301	21.8.3	Clinical and pathological findings	308
20.8	Concluding remarks and future directions	301	21.9	Inorganic arsenic	308
References		301	21.9.1	Sources and uses	309
21. Arsenicals: toxicity, their use as chemical warfare agents, and possible remedial measures	303		21.9.2	Toxicokinetics	309
<i>Sakshi Srivastava and Swaran J.S. Flora</i>			21.9.3	Biochemical and toxic effects	309
21.1	Introduction	303	21.9.4	Mechanisms of toxicity	311
21.2	Background	303	21.9.5	Diagnosis	311
			21.9.6	Chelating agents and chelation therapy	313
			21.9.7	Monoisoamyl DMSA	314
			21.10	Combination treatment	316
			21.11	Concluding remarks and future directions	317
			References		318
			22. Chlorine	321	
			<i>Sylvia Milanez</i>		
			22.1	Introduction	321
			22.2	History of use and human exposure	321
			22.3	Absorption, distribution, metabolism, and excretion	322
			22.4	Mechanistic studies	323
			22.5	Toxicity	324
			22.5.1	Human studies	324
			22.5.2	Laboratory animal studies	326
			22.6	Risk assessment	335
			22.7	Treatment	336
			22.8	Concluding remarks and future directions	336
			References		337

23. Phosgene	341	24.17 Toxicity of carbon monoxide	364
<i>Cheryl B. Bast and Dana F. Glass-Mattie</i>		24.17.1 Factors affecting susceptibility to poisoning	364
23.1 Introduction	341	24.17.2 Combined exposures to carbon monoxide, cyanides, and other toxicological gases in battlefield and military circumstances	364
23.2 Background	341	24.17.3 Acute toxicity	365
23.3 Toxicokinetics	341	24.17.4 Delayed (interval) manifestations of acute toxicity	366
23.4 Mechanism of action	342	24.18 Typical anatomic pathology findings	366
23.5 Toxicity	343	24.19 Treatment of carbon monoxide overdose	367
23.5.1 Human	343	24.19.1 Oxygen	367
23.5.2 Animal	343	24.19.2 Targeted temperature management	367
23.6 Risk assessment	344	24.19.3 Sympatholytics and sedation	367
23.7 Treatment	344	24.19.4 Allopurinol and <i>N</i> -acetylcysteine	367
23.8 Concluding remarks and future directions	345	24.19.5 Insulin	367
References	349	24.20 Acceptable exposure levels within the military context	367
24. Carbon monoxide: can't see, can't smell, body looks red but they are dead	353	24.21 Defensive measures	368
<i>Rhian B. Cope</i>		24.22 Concluding remarks and future directions	368
24.1 Introduction	353	References	369
24.2 Historical background	354	25. Acute cyanide toxicity and its treatment: the body is dead and may be red but does not stay red for long	373
24.3 Epidemiological considerations	355	<i>Rhian B. Cope</i>	
24.4 Physicochemical properties of carbon monoxide	355	25.1 Introduction: basic terminology and a brief and tragic history of the use and misuse of cyanide	373
24.5 Sources of carbon monoxide	355	25.2 Sources of exposure	376
24.5.1 External sources of carbon monoxide	356	25.3 Toxic levels of cyanide	377
24.5.2 Endogenous sources of carbon monoxide	356	25.4 Detection and estimation of cyanide	378
24.6 Methods for carbon monoxide measurement	356	25.5 Toxicokinetics of cyanide	379
24.7 Measurement of blood carbon monoxide	357	25.5.1 Absorption	379
24.8 Ambient air carbon monoxide	357	25.5.2 Distribution	379
24.9 Home detectors	357	25.5.3 Elimination	379
24.10 Carbon monoxide in expired breath	357	25.6 Mechanism of action	380
24.11 Toxicokinetics and toxicodynamics	358	25.7 Diagnosis and clinical features of cyanide poisoning	381
24.11.1 Absorption, distribution, and elimination of carbon monoxide	358	25.8 Treatment of cyanide poisoning	383
24.12 Mechanism of toxicity	361	25.8.1 Antidotal therapy	383
24.12.1 Classical mode of action	361	25.8.2 Methemoglobin inducers	383
24.12.2 Electrocardiographic/heart rhythm effects	362	25.8.3 Amyl nitrite	384
24.12.3 Cardiac hemodynamic effects	362	25.8.4 Sodium nitrite	384
24.12.4 Cardiomegaly	362	25.8.5 4-Dimethylaminophenol	384
24.12.5 Other cardiac effects	363	25.8.6 Sulfur donors	384
24.12.6 Effects on cerebral blood flow	363	25.8.7 Cobalt compounds	384
24.13 Effects on brain metabolism	363	25.8.8 Dicobalt edetate (Kelocyanor)	385
24.14 Redox and reoxygenation/reperfusion injuries in the brain	363		
24.15 The catecholamine crisis hypothesis	363		
24.16 Other possible mechanisms of central nervous system toxicity	363		

25.8.9 Hydroxocobalamin (Cyanokit)	385	Acknowledgment	410
25.8.10 Supportive therapy	385	References	410
25.9 Concluding remarks and future directions	385	28. Ricin	413
References	385	<i>Ramesh C. Gupta and Harry Salem</i>	
26. Methyl isocyanate: the Bhopal gas	389	28.1 Introduction	413
<i>Ramesh C. Gupta and Daya R. Varma</i>		28.2 History of biological weapons	414
26.1 Introduction	389	28.3 The weaponization of biological agents	415
26.2 The making of a disaster	389	28.4 The family of ribosome-inactivating proteins	416
26.3 Chemistry and toxicokinetics of isocyanates	390	28.5 The ricin toxin structure and biosynthesis	418
26.3.1 Chemistry of isocyanates	390	28.6 The cellular internalization of ricin	419
26.4 Mechanism of death following exposure to methyl isocyanate	392	28.7 N-Glycosidase activity of ricin	420
26.5 The cyanide controversy	392	28.8 Signs and symptoms of ricin exposure	420
26.6 Toxicity of isocyanates	393	28.9 Field-forward biological agent detection	421
26.7 Toxicity of methyl isocyanate	393	28.9.1 Immunoassays	421
26.7.1 Toxicity of methyl isocyanate in animal models	394	28.9.2 DNA-based assays: polymerase chain reaction	422
26.7.2 Toxicity in humans	395	28.10 Concluding remarks and future directions	423
26.8 Treatment	397	References	424
26.9 Toxic potential of methyl isocyanate beyond the Bhopal disaster	398	29. Botulinum toxin	427
26.10 Benzyl chlorines and other chemicals at Bhopal	398	<i>Rhian B. Cope</i>	
26.11 Concluding remarks and future directions	399	29.1 Introduction	427
Acknowledgments	399	29.2 Historical aspects	427
References	399	29.3 Background	429
27. Other toxic chemicals as potential chemical warfare agents	403	29.3.1 Toxin structure and molecular function	429
<i>Jiri Bajgar, Jiri Kassa, Josef Fusek, Kamil Kuca and Daniel Jun</i>		29.3.2 Overview of botulinum neurotoxin action	430
27.1 Introduction	403	29.3.3 Clinical forms of botulism in humans and animals	430
27.2 General	403	29.3.4 Infectious forms of botulism	431
27.2.1 Chemical weapons convention: article II, definitions and criteria	403	29.3.5 Noninfectious forms of botulism	432
27.3 Specific agents	404	29.3.6 Human intoxication	432
27.3.1 Carbamates	404	29.4 Epidemiology	433
27.3.2 Dioxin	405	29.4.1 Foodborne botulism	433
27.3.3 Bicyclic phosphates	405	29.5 Pathogenesis	435
27.3.4 Perfluoroisobutene	405	29.5.1 Overview of pathogenesis	435
27.3.5 Organophosphates	405	29.5.2 Toxin stability	436
27.3.6 Toxins	406	29.5.3 Oral intoxication: toxin absorption from the gastrointestinal tract	437
27.3.7 Bioregulators	407	29.5.4 Respiratory intoxication	438
27.3.8 Thyroid-stimulating hormone	409	29.5.5 Toxin binding and uptake into target tissues	439
27.4 Nonlethal weapons	409	29.6 Toxicokinetics	439
27.4.1 Genetic and ethnic weapons	409	29.6.1 Foodborne toxicity	439
27.5 Concluding remarks and future directions	410	29.6.2 Inhalation toxicity	441
		29.7 Mechanism of action	442
		29.7.1 Heavy chain	442
		29.7.2 Light chain	443

29.8 Toxicity	444		
29.8.1 Lethality	444		
29.8.2 Oral toxicity	446		
29.8.3 Inhalation toxicity	446		
29.8.4 Clinical toxicity	446		
29.9 Risk assessment	447		
29.10 Treatment	448		
29.10.1 Antitoxin	448		
29.10.2 Treatment for infant botulism	448		
29.10.3 Vaccines	449		
29.11 Concluding remarks and future directions	449		
29.11.1 Development of animal model test systems	449		
References	450		
30. Onchidal and fasciculins	455		
<i>Arturo Anadón, María-Rosa Martínez-Larrañaga and Luis G. Valerio</i>			
30.1 Introduction	455		
30.2 Background	456		
30.2.1 Onchidal	456		
30.2.2 Fasciculin	457		
30.3 Mechanism of action and biological effects	458		
30.3.1 Onchidal	458		
30.3.2 Fasciculin	459		
30.4 Experimental and human toxicity	460		
30.4.1 Experimental	460		
30.4.2 Human	461		
30.5 Computational toxicology assessment	462		
30.6 Treatment	463		
30.7 Concluding remarks and future directions	464		
30.8 Disclosures	464		
Acknowledgments	464		
References	464		
31. Cyanobacterial (blue-green algae) toxins	467		
<i>Jitendra K. Malik, Vijay K. Bharti, Anu Rahal, Dinesh Kumar and Ramesh C. Gupta</i>			
31.1 Introduction	467		
31.2 Hepatotoxins	468		
31.2.1 Microcystins and nodularins	468		
31.2.2 Cylindrospermopsin	471		
31.3 Neurotoxins	473		
31.3.1 Anatoxin-a	473		
31.3.2 Anatoxin-a(s)	474		
31.3.3 Saxitoxins	475		
31.4 Concluding remarks and future directions	475		
References	476		
		Section III	
		Target Organ Toxicity	479
		32. Chemical warfare agents and the nervous system	481
		<i>Jing Liu, Linzzi K. Wright and Carey N. Pope</i>	
		32.1 Introduction	481
		32.2 Overview of the nervous system	481
		32.2.1 Special features of neurons and high energy demand	483
		32.2.2 Blood–brain barrier	484
		32.3 Types of neurotoxicity	484
		32.4 Selected chemical warfare agents that affect the nervous system	484
		32.4.1 Organophosphorus nerve agents	485
		32.4.2 Cyanides	490
		32.4.3 Sulfur mustard	491
		32.4.4 3-Quinuclidinyl benzilate	492
		32.5 Concluding remarks and future directions	492
		References	493
		33. Behavioral toxicity of nerve agents	499
		<i>Jiri Kassa, Jiri Bajgar, Kamil Kuča and Daniel Jun</i>	
		33.1 Introduction	499
		33.2 The methods used to evaluate the behavioral effects of nerve agents	499
		33.2.1 Functional observatory battery	499
		33.2.2 Performance on the RAM task	502
		33.2.3 Acoustic startle response and prepulse inhibition	502
		33.2.4 Performance on the Y-maze	502
		33.2.5 Performance on the T-maze	503
		33.2.6 Performance on the Morris water maze	503
		33.2.7 Performance on the passive avoidance test	503
		33.2.8 Performance on the Barnes maze	504
		33.3 Long-term behavioral effects of acute high-level exposure to nerve agents	504
		33.4 Chronic behavioral effects of single or repeated low-level exposure to nerve agents	506
		33.5 Concluding remarks and future directions	509
		References	510
		34. The respiratory toxicity of chemical warfare agents	515
		<i>Alfred M. Sciuto and Urmila P. Kodavanti</i>	
		34.1 Introduction	515

34.2	History of chemical warfare agents use	515	35.7	Therapeutics under development	559
34.3	The respiratory system	516	35.8	Concluding remarks and future directions	560
34.4	Pulmonary agents	517	35.8.1	Current concerns	560
34.4.1	Arsine	517	35.8.2	Potential future scenarios	561
34.4.2	Chlorine	518	35.9	A new approach	561
34.4.3	Phosgene	520	References	561	
34.4.4	Nerve agents	521			
34.4.5	Nonvolatile agents	525			
34.4.6	Cyanides	527	36. Ocular toxicity of chemical warfare agents	567	
34.4.7	Riot control agents	528	<i>Patrick M. McNutt, Tracey A. Hamilton, Megan E. Lyman and Marian R. Nelson</i>		
34.4.8	DA and DC	534	36.1	Introduction	567
34.4.9	Vesicating agents	535	36.2	Background	568
34.5	Concluding remarks and future directions	538	36.2.1	The structure of the eye	568
Acknowledgments		538	36.2.2	Effects of ocular structure on regenerative capacities	569
References		539	36.2.3	Importance of neurological function to vision	571
35. The cardiovascular system as a target of chemical warfare agents	545		36.3	Ocular toxicities of specific chemical warfare agents	572
<i>Csaba K. Zoltani</i>			36.3.1	Selection of agents discussed	572
35.1	Introduction	545	36.4	Vesicants (Group 1)	572
35.1.1	Potential indicators	545	36.4.1	The mustard gases	573
35.1.2	Hazard models	547	36.4.2	Lewisite	579
35.2	Background	547	36.4.3	Phosgene oxime	579
35.2.1	Cardiac anatomy	547	36.5	Nerve agents	580
35.2.2	Innervation of the heart	548	36.6	Psychomimetic incapacitating agents	581
35.2.3	Neuropeptides	548	36.7	Blood agents	581
35.2.4	Energetics of the heart	549	36.8	Choking agents	582
35.2.5	Electrophysiology	549	36.9	Riot control agents	582
35.3	Signatures of cardiac toxicity	549	36.10	Biological toxins	583
35.3.1	The electrocardiogram as a diagnostic tool for poisoning	549	36.10.1	Botulinum neurotoxins (BoNTs)	583
35.3.2	Biochemical markers of tissue injury	551	36.10.2	Ricin	584
35.4	Indices of the toxicity of warfare agents	552	36.10.3	<i>Staphylococcus</i> enterotoxin B (SEB)	585
35.4.1	Classes of warfare agents	552	36.11	Concluding remarks and future directions	585
35.4.2	Background	552	Disclaimer	585	
35.4.3	Signatures of toxicity	552	References	585	
35.4.4	Nerve agents	552			
35.4.5	Electrocardiographic signature of organophosphates	553	37. Skeletal muscle	589	
35.5	Specific warfare agents of concern regarding the heart	554	<i>Ramesh C. Gupta, Robin B. Doss, Snjezana Zaja-Milatovic, Wolf-D. Dettbarn and Jitendra K. Malik</i>		
35.5.1	Currently the most widely used agents rely on organophosphate compounds	554	37.1	Introduction	589
35.5.2	Antidotes for organophosphate nerve agents	556	37.2	Behavioral effects	589
35.5.3	Cyanide	556	37.3	Cholinergic system	590
35.6	Other terror agents	558	37.3.1	Normal activity of acetylcholinesterase and its molecular forms	590
35.6.1	Arsenic	558			
35.6.2	Ricin	559			

37.3.2	Inhibition of acetylcholinesterase and its molecular forms by nerve agents	591	38.4.3	Decontamination	622
37.3.3	Butyrylcholinesterase	592	38.4.4	Treatment of blisters	623
37.3.4	Choline acetyltransferase	593	38.5 Therapeutics		623
37.3.5	Acetylcholine receptors	593	38.5.1	Antioxidants	623
37.4 Noncholinergic system		595	38.5.2	Poly(ADP-ribose) polymerase inhibitors	626
37.4.1	Muscle excitotoxicity	595	38.5.3	Proteolytic inhibitors	626
37.4.2	Oxidative/nitrosative stress	596	38.5.4	Steroids, corticosteroids, and glucocorticoids	627
37.4.3	High-energy phosphate depletion and myonecrosis	597	38.5.5	Nonsteroidal antiinflammatory drugs	628
37.5 Muscle activity—electromyography		598	38.5.6	Bifunctional compounds	628
37.6 Muscle fiber histopathology		599	38.5.7	Transient receptor potential ligands	629
37.7 Muscle cytotoxicity biomarkers		602	38.5.8	Cooling	629
37.7.1	Creatine kinase and creatine kinase isoenzymes	602	38.6 Concluding remarks and future directions		630
37.7.2	Lactate dehydrogenase and lactate dehydrogenase isoenzymes	603	References		630
37.8 Skeletal muscle involvement in tolerance development		603	39. Reproductive toxicity and endocrine disruption of potential chemical warfare agents		641
37.9 Skeletal muscle involvement in intermediate syndrome		605	<i>Tim J. Evans</i>		
37.10 Prevention/treatment of myopathy		605	39.1 Introduction		641
37.11 Acetylcholinesterase reactivators and acetylcholinesterase receptor blockers		605	39.2 Important definitions and concepts		642
37.11.1	<i>N</i> -Methyl-D-aspartate receptor antagonist	606	39.2.1	Chemical warfare agents	642
37.11.2	Anticonvulsants and anesthetics	607	39.2.2	Environmental contaminants associated with industrial or agricultural terrorism	642
37.11.3	Antioxidants, spin-trapping agents, and creatine	607	39.2.3	Reproduction	643
37.12 Concluding remarks and future directions		608	39.2.4	Reproductive toxicity	643
Acknowledgment		608	39.3 The reproductive toxicity of selected toxicants		646
References		608	39.3.1	The reproductive toxicity of riot control agents	647
38. Dermal toxicity of sulfur mustard		613	39.3.2	The reproductive toxicity of chemical warfare agents	647
<i>Joshua P. Gray, Michael P. Shakarjian, Donald R. Gerecke and Robert P. Casillas</i>			39.4 Conclusion		653
38.1 Introduction		613	References		654
38.2 Background		613	40. Liver toxicity of chemical warfare agents		659
38.2.1	Military use	613	<i>Atrayee Banerjee</i>		
38.2.2	Wound repair	613	40.1 Introduction		659
38.3 Pathogenesis		614	40.2 Structural organization of the liver		659
38.3.1	Cytotoxicity of sulfur mustard	615	40.2.1	Hepatic functional capacity	660
38.3.2	Inflammation	617	40.2.2	Hepatic cellular components	660
38.3.3	Protease activation	618	40.3 Factors influencing hepatic toxicity		661
38.3.4	Apoptosis	618	40.3.1	Preferential hepatic uptake	661
38.3.5	Signal transduction pathways	619	40.3.2	Xenobiotic metabolic bioactivation	661
38.4 Models of dermal sulfur mustard exposure		619	40.3.3	Phase II/conjugation reactions	661
38.4.1	Introduction	619	40.3.4	Phase III reactions	662
38.4.2	Model systems for screening sulfur mustard	620			

43.16	Early radiation effects from internally deposited radionuclides	725	45.	Neurological effects and mechanisms of blast overpressure injury	767
	43.16.1 Radiation-induced cancer in humans from acute exposures	728		<i>Jason Pitt</i>	
43.17	Linear nonthreshold models	734	45.1	Introduction	767
43.18	Current radiation protection guidance	736	45.2	Blast waves and mechanisms of injury	767
43.19	Summary	738		45.2.1 Pressure waves	768
43.20	Personal perspective	739		45.2.2 Mechanism of primary injury	769
43.21	Dedication	739	45.3	Clinical features of traumatic brain injury	769
References		740		45.3.1 Common clinical features of traumatic brain injury	770
				45.3.2 Distinct clinical features of blast traumatic brain injury	772
44.	Clinical and cellular aspects of traumatic brain injury	745	45.4	Human neuropathology of blast traumatic brain injury	772
	<i>Jason Pitt, Yiuka Pitt and Jordana Lockwich</i>			45.4.1 Neuropathological features of blast traumatic brain injury	772
44.1	Introduction	745		45.4.2 Clinical management	773
44.2	Traumatic brain injury mouse models	745	45.5	Animal models of blast traumatic brain injury	774
44.3	Clinical manifestations and management of traumatic brain injury	746	45.6	Biomarkers of blast injury	775
	44.3.1 Classifying traumatic brain injury using the Glasgow Coma Scale	746		45.6.1 Serum and cerebrospinal fluid protein biomarkers	775
	44.3.2 Coma recovery scale to track meaningful changes with severe traumatic brain injury	747	45.7	Concluding remarks and future directions	776
	44.3.3 Intracranial pressure	748	References		776
	44.3.4 Primary and secondary brain injury	750			
	44.3.5 Immediate care	752	46.	Genomics and proteomics in brain complexity in relation to chemically induced posttraumatic stress disorder	779
	44.3.6 Surgical management	752		<i>Gopala Krishna and Mayur Krishna</i>	
	44.3.7 Targeted therapies to prevent secondary injury	752	46.1	Introduction	779
44.4	Maintenance of adequate cerebral perfusion improves outcome after traumatic brain injury	752	46.2	The effect of posttraumatic stress disorder on different regions of brain	780
	44.4.1 Other targeted therapies	753	46.3	The hypothalamic–pituitary–adrenal axis	780
	44.4.2 Opportunities for rehabilitation and recovery posttraumatic brain injury	753	46.4	Hippocampus	780
44.5	Cognitive impairments	754	46.5	Amygdala	781
	44.5.1 Neuronal loss	754	46.6	Cortex	781
	44.5.2 Synapse loss	755	46.7	Understanding posttraumatic stress disorder: the genomics and proteomics way	782
	44.5.3 Seizures	756	46.8	Applications of genomic and transcriptomics methods	783
44.6	Cellular mechanisms of primary and secondary injuries	757	46.9	Role of noncoding RNAs and epigenetics in posttraumatic stress disorder	785
	44.6.1 Necrosis	757	46.10	Toxic chemical exposure and human diseases	786
	44.6.2 Apoptosis	758	46.11	Genomic applications: understanding the relationship between posttraumatic stress disorder and chemical toxicity	786
44.7	Potential mechanisms of synaptic impairment	761	46.12	Proteomics	787
44.8	Pathological hallmarks of Alzheimer's disease in traumatic brain injury	761			
	44.8.1 Alzheimer's disease: A β and tau	761			
	44.8.2 A β in traumatic brain injury	762			
	44.8.3 Tau in traumatic brain injury	762			
44.9	Concluding remarks and future directions	762			
References		763			

46.13	Neuroproteomics: proteomics applications in neuroscience	788	48.7.4	Drugs of abuse-induced BBB damage	819
46.14	Proteomics approaches to understand natural and chemical toxicity-induced posttraumatic stress disorder	788	48.7.5	Metals	819
46.15	Concluding remarks and future directions	789	48.8	Bacterial toxin-induced BBB damage	820
Acknowledgment		789	48.9	GWI and the BBB	820
References		789	48.10	Effects of blasts on the BBB	821
47. Excitotoxicity, oxidative stress, and neuronal injury		795	48.11	Excitotoxicity, stress, and the BBB	821
<i>Snjezana Zaja-Milatovic and Ramesh C. Gupta</i>			48.12	Brain barriers and CNS diseases	822
47.1	Introduction	795	48.13	Melatonin and the BBB	823
47.2	Excitotoxicity and oxidative injury	796	48.14	Concluding remarks and future directions	823
47.3	Lipid peroxidation and in vivo markers of oxidative damage	797	Acknowledgment		823
47.4	Anti-AChE-induced seizures, oxidative injury, and neurodegeneration	799	References		823
47.5	Oxidative damage and dendritic degeneration following KA-induced excitotoxicity	801	49. The effects of organophosphates in the early stages of human skeletal muscle regeneration		829
47.6	Suppression of seizure-induced oxidative injury and neurodegeneration	802	<i>Tomaz Mars, Katarina Mis, Maja Katalinic, Katarina Pegan, Zoran Grubic and Sergej Pirkmajer</i>		
47.6.1	Antioxidants	802	49.1	Introduction	829
47.6.2	N-methyl-D-aspartate receptor antagonist (memantine)	804	49.2	Regeneration process in human skeletal muscle	831
47.7	Concluding remarks and future directions	806	49.3	Noncholinergic effects of DFP in regenerating human skeletal muscle	831
Acknowledgment		806	49.3.1	The effect of DFP on IL-6 secretion from myoblasts and myotubes	831
References		806	49.3.2	Heat shock proteins in human myoblasts and myotubes after treatment with DFP	832
48. Blood–brain barrier damage and dysfunction by chemical toxicity		811	49.3.3	Response of human myoblasts to hypoxia	833
<i>Ramesh C. Gupta, Jason Pitt and Snjezana Zaja-Milatovic</i>			49.3.4	The effects of DFP on the NRE activity in human myoblasts	833
48.1	Introduction	811	49.4	Expression and role of AChE in human myoblasts	834
48.2	Structure and function of the BBB	812	49.4.1	Recovery of AChE mRNA expression and AChE activity after gene silencing of AChE and after exposure to DFP	834
48.3	In vivo and in vitro models to study the BBB	812	49.4.2	The role of AChE in myoblast apoptosis	836
48.3.1	In vivo model	813	49.5	Concluding remarks and future directions	837
48.3.2	In vitro models	813	Acknowledgments		837
48.4	Gender differences in the BBB	814	References		837
48.5	The BBB in young and adult brains	815	50. Experimental modeling for delayed effects of organophosphates		843
48.6	Transport of molecules across the BBB	815	<i>Nikolay Goncharov, Daria Belinskaia, Vladimir Shmurak, Ekaterina Korf, Richard Jenkins and Pavel Avdonin</i>		
48.7	Effects of toxic agents on the BBB	817	50.1	Introduction and background	843
48.7.1	Anticholinesterase organophosphate nerve agents	817	50.2	Experimental procedures	844
48.7.2	Oxime reactivators of AChE inhibited by OPs and the BBB	818			
48.7.3	NMDAR antagonist memantine and the BBB	818			

53.5.2	Experimental animal studies on cholinesterase inhibition and acute toxicity	932	55.3	Esterases involved in the metabolism of warfare nerve agents	956
53.5.3	Studies in man	933	55.3.1	A-esterases	956
53.6	DFP in studies on neurotoxicity and therapy with reactivators	933	55.3.2	B-esterases	958
53.6.1	Neuropharmacological studies of the cholinergic system	933	55.4	Lipase	962
53.6.2	Neurobehavior and neurodevelopment	934	55.5	Protein binding	962
53.6.3	Therapy against anticholinesterase toxicity	935	55.6	Concluding remarks and future directions	962
53.6.4	DFP in other biological studies	935	References	963	
53.7	Interaction of DFP with other esterases	935	Section VI		
53.7.1	Serine proteases and albumin: role of tyrosine residues	935	Analytical methods, biosensors and biomarkers		
53.7.2	Inhibition of soluble PVases of peripheral nerve by DFP	935	967		
53.7.3	DFP- and OP-induced delayed neuropathy and neuropathy target esterase	936	56. Laboratory analysis of chemical warfare agents, adducts, and metabolites in biomedical samples		
53.8	Concluding remarks and future directions	938	969		
References	938	<i>M.J. van der Schans</i>			
54. Physiologically based pharmacokinetic modeling of chemical warfare agents	945	56.1 Introduction			969
<i>Jeffery M. Gearhart, Peter J. Robinson and Edward M. Jakubowski</i>		56.2 Nerve agents			970
54.1	Introduction	945	56.2.1	Analysis of intact nerve agents	970
54.2	Development of PBPK models	946	56.2.2	Verification of exposure to nerve agents	971
54.3	Need for improved measures of CWNA exposure—the use of PBPK analysis of data	947	56.3	Sulfur mustard and lewisite	973
54.4	Relationship between regenerated sarin and AChE activity and its use as a dose surrogate	948	56.4	Concluding remarks and future directions	975
54.5	General PBPK model structure	948	References	976	
54.6	PBPK simulation of cholinesterase inhibition and regenerated GB	949	57. On-site detection of chemical warfare agents		
54.7	Concluding remarks and future directions	951	983		
References	952	<i>Yasuo Seto</i>			
55. Biotransformation of warfare nerve agents	953	57.1	Introduction	983	
<i>Milan Jokanović, Dragana Ristić, Bojan Kovač and Miloš P. Stojiljković</i>		57.2	Properties of chemical warfare agents	983	
55.1	Introduction	953	57.3	Concept of on-site detection	984
55.2	Chemical aspects of biotransformation of nerve agents	954	57.4	The present situation of detection technology	987
			57.4.1	Classical manual method	987
			57.4.2	Photometric method	989
			57.4.3	Ion mobility spectrometry method	989
			57.4.4	Vibrational spectroscopy	993
			57.4.5	Gas chromatography	993
			57.4.6	Mass spectrometry	994
			57.4.7	Other sensor technologies	994
			57.5	Comparison of existing on-site detection technologies	997
			57.6	Development of new on-site detection technologies	997
			57.7	Concluding remarks and future directions	997
			References	1000	

58. Neuropathy target esterase as a biomarker and biosensor of delayed neuropathic agents	1005	59. The cross-linking action of organophosphorus poisons; Implications for chronic neurotoxicity	1027
<i>Rudy J. Richardson, John K. Fink, R. Mark Worden, Sanjeeva J. Wijeyesakere and Galina F. Makhaeva</i>		<i>Oksana Lockridge and Lawrence M. Schopfer</i>	
58.1 Introduction	1005	59.1 Introduction	1027
58.2 Organophosphorus compounds	1005	59.2 Chemical reactions of organophosphorus poisons	1027
58.2.1 Conventional nerve agents versus delayed neuropathic agents	1005	59.3 Cross-linking mechanism	1028
58.2.2 Organophosphorus compounds of pentavalent versus trivalent phosphorus	1006	59.4 Mass spectrometry identifies cross-linked peptides	1028
58.3 Organophosphorus compound–induced delayed neurotoxicity	1007	59.5 The consequences of treating tubulin with chlorpyrifos oxon	1029
58.4 Neuropathy target esterase	1008	59.6 Implications for neurotoxicity	1030
58.4.1 Definition of neuropathy target esterase and its potential normal or pathogenic roles	1008	59.7 Zero-length cross-links between lysine and glutamic acid or lysine and aspartic acid	1030
58.4.2 Role of neuropathy target esterase in organophosphorus compound–induced delayed neurotoxicity	1009	59.8 Concluding remarks	1031
58.5 Kinetics of organophosphorus inhibitor–serine hydrolase interactions	1010	References	1031
58.5.1 Introduction	1010	60. Monitoring of blood cholinesterase activity in workers exposed to nerve agents	1035
58.5.2 Inhibition	1011	<i>Daniel Jun, Jiri Bajgar, Kamil Kuca and Jiri Kassa</i>	
58.5.3 Reactivation	1012	60.1 Introduction	1035
58.5.4 Aging	1013	60.2 Determination of cholinesterases	1036
58.5.5 Relative inhibitory potency	1013	60.3 Factors influencing the activity of cholinesterases	1037
58.6 Biomarkers	1014	60.4 Diagnosis of organophosphorus compound poisoning	1038
58.6.1 Introduction	1014	60.5 Monitoring of blood cholinesterase activity in workers exposed to nerve agents	1040
58.6.2 Enzymological measurements of neuropathy target esterase inhibition and aging	1015	60.5.1 Introduction	1040
58.6.3 Identification of neuropathy target esterase–organophosphorus conjugates using mass spectrometry	1015	60.5.2 Methods for determination	1040
58.7 Biosensors	1017	60.5.3 Correlation among methods	1040
58.7.1 Nanostructured electrochemical biosensors to measure enzyme activity	1017	60.5.4 Subjects	1040
58.7.2 Electrochemical biosensor arrays for high-throughput analysis	1018	60.5.5 Statistical analysis	1041
58.7.3 Assembly of electrochemical biosensor interfaces for serine hydrolases	1018	60.5.6 Results and discussion	1041
58.7.4 Electrochemical measurements of serine esterase activity	1019	60.6 Concluding remarks	1042
58.8 Concluding remarks and future directions	1020	Acknowledgments	1042
References	1020	References	1042
		Section VII	
		Risks to animals and wildlife	1047
		61. Potential agents that can cause contamination of animal feedingstuff and terror	1049
		<i>Robert W. Coppock and Margitta M. Dziwenka</i>	
		61.1 Introduction	1049

61.1.1	Agricultural food ecosystem and terror	1051		
61.2	Mycotoxins and toxigenic fungi	1051		
61.2.1	Background	1051		
61.2.2	Applications of biotechnology	1052		
61.2.3	Fungal biocontrol agents	1052		
61.2.4	Economic losses from the use of fungi and mycotoxins as weapons	1052		
61.2.5	Terrorism using mycotoxin-contaminated feedingstuff	1052		
61.2.6	Residues in edible tissues	1052		
61.3	Microbial toxins	1053		
61.3.1	Botulism toxin	1053		
61.4	Plant toxins	1053		
61.4.1	Toxins in seeds	1053		
61.4.2	Castor beans (ricin)	1053		
61.4.3	Other plant source type 2 RIPs	1055		
61.5	Rapidly acting and easily available substances	1055		
61.5.1	Cyanide	1055		
61.5.2	Insecticides and drugs	1056		
61.6	Persistent organic compounds	1056		
61.6.1	Background	1056		
61.6.2	Potential economics of terror attacks using persistent organic pollutants	1057		
61.7	Heavy metals and metalloids	1057		
61.7.1	Lead	1057		
61.7.2	Arsenic	1057		
61.8	Concluding remarks and future directions	1058		
	References	1058		
62.	Chemical warfare agents and risks to animal health	1061		
	<i>Tina Wismer</i>			
62.1	Introduction	1061		
62.2	Chemical warfare agents	1062		
62.2.1	Chlorine gas	1062		
62.2.2	Phosgene	1062		
62.2.3	Mustard gas	1063		
62.2.4	Lewisite	1064		
62.2.5	Phosgene oxime	1066		
62.2.6	Cyanide and hydrogen cyanide	1066		
62.2.7	Military nerve agents	1067		
62.2.8	3-Quinuclidinyl benzilate	1069		
62.2.9	RCAs (lacrimators)	1070		
62.2.10	Ricin and abrin (toxalbumins)	1071		
62.3	Concluding remarks and future directions	1072		
	References	1072		
63.	Threats to wildlife by chemical and warfare agents	1077		
	<i>Robert W. Coppock and Margitta M. Dziwenka</i>			
63.1	Introduction	1077		
63.2	Infrastructure and potential widespread chemical contamination	1078		
63.3	Pyroterrorism and wildlife	1079		
63.4	Candidate chemical agents	1079		
63.4.1	Background	1079		
63.5	Selected pesticides	1082		
63.5.1	Background	1082		
63.5.2	Incidents of intoxication	1083		
63.6	Castor bean (<i>Ricinus communis</i>)	1083		
63.6.1	Background	1083		
63.6.2	Toxicology and pathology	1083		
63.6.3	Water baits	1084		
63.7	Concluding remarks and future directions	1084		
	References	1084		
	Section VIII			
	Prophylactic, therapeutic and countermeasures			1089
64.	Pharmacological prophylaxis against nerve agent poisoning: experimental studies and practical implications	1091		
	<i>Jiri Bajgar, Josef Fusek, Jiri Kassa, Kamil Kuca and Daniel Jun</i>			
64.1	Introduction	1091		
64.2	Protection of acetylcholinesterase against inhibition	1092		
64.3	Scavengers	1093		
64.4	Prophylaxis with current antidotes	1094		
64.5	Prophylactic use of other drugs	1094		
64.6	Concluding remarks and future directions	1097		
	Acknowledgment	1097		
	References	1097		
65.	Prophylactic and therapeutic measures in nerve agents poisonings	1103		
	<i>Miloš P. Stojiljković, Milan Jokanović, Dragana Lončar-Stojiljković and Ranko Škrbić</i>			
65.1	Introduction	1103		
65.2	Prophylaxis against intoxication with nerve agents	1104		
65.2.1	Use of acetylcholinesterase inhibitors in prophylaxis of poisoning with nerve agents	1105		
65.2.2	Prophylactic use of oximes	1107		

65.2.3	Use of <i>N</i> -methyl-D-aspartate-receptor-blocking drugs in prophylaxis against organophosphorus compounds	1107		
65.2.4	Adverse effects of prophylactic regimens	1109		
65.2.5	Bioscavengers against nerve agents	1109		
65.3	Treatment of intoxication with nerve agents	1109		
65.3.1	Anticholinergics	1109		
65.3.2	Acetylcholinesterase reactivators	1110		
65.3.3	Anticonvulsants	1111		
65.4	Concluding remarks and further directions	1113		
	References	1113		
66.	Physiologically based pharmacokinetic/pharmacodynamic modeling of countermeasures to nerve agents	1121		
	<i>Elaine Merrill, Chris Ruark, Jeffery M. Gearhart and Peter Robinson</i>			
66.1	Introduction	1121		
66.2	Background	1121		
66.3	Current countermeasures	1122		
66.4	Novel countermeasures	1122		
66.5	PBPK/PD modeling	1123		
66.6	Development of PBPK/PD models	1124		
66.7	Experimental and QSAR methodologies to predict blood and tissue partition coefficients	1125		
66.8	Interaction PBPK/PD model for NAs and countermeasures	1127		
66.9	Health effects assessment and countermeasure optimization	1130		
66.10	Concluding remarks and future directions	1131		
	References	1132		
67.	Research on medical countermeasures for chemical attacks on civilians	1135		
	<i>Shardell M. Spriggs, Gennady E. Platoff Jr. and David A. Jett</i>			
67.1	Introduction	1135		
67.2	Medical countermeasures used in civilian chemical incidents	1136		
67.3	Research needs for civilian medical countermeasures	1137		
67.4	Research at the National Institutes of Health in the United States	1138		
67.5	Contract core facilities	1139		
67.6	Scope of research	1140		
67.7	Research on medical countermeasures for civilian chemical threats	1140		
67.8	Concluding remarks and future directions	1142		
	References	1143		
68.	Pyridinium oximes in the treatment of poisoning with organophosphorus compounds	1145		
	<i>Milan Jokanović, Miloš P. Stojiljković, Bojan Kovač and Dragana Ristić</i>			
68.1	Introduction	1145		
68.2	Interaction of cholinesterases with organophosphorus inhibitors	1145		
68.3	Clinical aspects of acute organophosphorus poisoning	1146		
68.4	Antidotes in the treatment of organophosphorus poisoning	1147		
68.4.1	Atropine	1147		
68.4.2	Diazepam	1148		
68.4.3	Oximes	1148		
68.5	Pyridinium oximes in the management of poisoning with warfare nerve agents	1149		
68.5.1	Pralidoxime (PAM-2)	1149		
68.5.2	Trimedoxime (TMB-4)	1150		
68.5.3	Obidoxime (LüH-6, toxogonin)	1150		
68.5.4	Asoxime (HI-6)	1151		
68.5.5	HLö-7	1151		
68.5.6	Methoxime (MMB-4)	1152		
68.6	Pyridinium oximes in the management of poisoning with organophosphorus pesticides	1152		
68.7	Concluding remarks and future directions	1155		
	References	1155		
69.	Novel cholinesterase reactivators	1161		
	<i>Kamil Musilek, David Malinak, Eugenie Nepovimova, Rudolf Andrys, Adam Skarka and Kamil Kuca</i>			
69.1	Introduction	1161		
69.2	OP AChE inhibitors	1161		
69.3	Acetylcholinesterase (AChE; EC 3.1.1.7)	1162		
69.4	Antidotes for AChE inhibited by OP compounds	1163		
69.5	Design and synthesis of new AChE and BChE reactivators	1164		
69.6	Uncharged non-oxime reactivators	1164		
69.7	Uncharged oxime reactivators	1165		
69.8	Mono- or double-charged oxime reactivators	1168		
69.9	In vitro evaluation of selected AChE reactivators	1172		
69.10	The structure–activity relationship and discussion	1173		

69.11 Recent trends in the development of new AChE reactivators and future directions	1174	72.2 Stoichiometric scavengers	1201
69.12 Concluding remarks and future directions	1174	72.3 Pseudocatalytic bioscavengers	1202
Acknowledgments	1174	72.4 Catalytic scavengers	1203
References	1174	72.5 Requirements	1203
70. Paraoxonase (PON1), detoxification of nerve agents, and modulation of their toxicity	1179	72.6 Potential enzymes	1205
<i>Lucio G. Costa, Toby B. Cole, Jacqueline Garrick, Judit Marsillach and Clement E. Furlong</i>		72.6.1 Phosphotriesterases	1205
70.1 Introduction	1179	72.6.2 Other enzymes	1209
70.2 PON1 polymorphisms: defining PON1 status	1179	72.6.3 Engineered cholinesterases and carboxylesterases	1210
70.3 PON1 and the toxicity of OP insecticides	1180	72.7 Concluding remarks and future directions	1217
70.4 PON1 and the toxicity of nerve agents	1182	Acknowledgment	1218
70.5 PON1 as a therapeutic agent	1184	References	1218
70.6 Concluding remarks and future directions	1185		
Acknowledgment	1186		
References	1186		
71. The role of carboxylesterases in therapeutic interventions of nerve agent poisoning	1191		
<i>Miloš P. Stojiljković, Milan Jokanović, Dragana Lončar-Stojiljković and Ranko Škrbić</i>			
71.1 Introduction	1191		
71.2 Enzymology of carboxylesterase	1191		
71.3 Carboxylesterase reactivation	1192		
71.4 Source and induction of carboxylesterase activity	1192		
71.5 Carboxylesterases as scavengers of nerve agents	1193		
71.6 Toxicity of nerve agents and carboxylesterase	1194		
71.7 Carboxylesterase inhibitors	1194		
71.8 Carboxylesterase and prophylactic/therapeutic interventions	1195		
71.9 Stoichiometric and catalytic scavengers of organophosphorus compounds	1195		
71.10 Concluding remarks and future directions	1196		
References	1196		
72. Catalytic bioscavengers: the second generation of bioscavenger-based medical countermeasures	1199		
<i>Patrick Masson and Sofya V. Lushchekina</i>			
Abbreviations	1199		
72.1 Introduction	1199		
		Section IX	
		Decontamination and detoxification	1231
		73. Rapid decontamination of chemical warfare agents from skin	1233
		<i>Edward D. Clarkson and Richard K. Gordon</i>	
		Abbreviations	1233
		73.1 Background: the nature of human skin	1233
		73.2 Background: nerve agents	1234
		73.3 Background: vesicating agents (distilled sulfur mustard, HD; impure sulfur mustard, H; Lewisite, L)	1235
		73.4 Model systems to measure absorption, removal, and decontamination	1236
		73.4.1 Rats	1236
		73.4.2 Guinea pigs	1236
		73.4.3 Swine	1237
		73.5 Decontamination requirements	1237
		73.6 Decontamination schemes	1238
		73.6.1 Classical liquid: sodium hypochlorite (bleach)	1238
		73.6.2 Powder decontamination material: M291 SDK	1239
		73.6.3 Liquid decontamination material: Sandia foam	1240
		73.6.4 Liquid decontamination material: Diphotérine	1240
		73.6.5 Liquid and sponges: Reactive Skin Decontamination Lotion	1241
		73.6.6 Polyurethane sponge	1242
		73.6.7 Immobilized enzyme badges	1243
		73.7 Concluding remarks and future directions	1244
		References	1244
		Index	1249

List of contributors

- Arturo Anadón** Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Complutense University of Madrid, Madrid, Spain
- Rudolf Andrys** University of Hradec Kralove, Faculty of Science, Department of Chemistry, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republic
- Pavel Avdonin** Koltzov Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia
- Jiri Bajgar** Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic; Faculty of Military Health Sciences, University of Defense, Hradec Kralove, Czech Republic; University Hospital Hradec Kralove, Sokolska, Czech Republic
- Mahdi Balali-Mood** Medical Toxicology Research Centre; Department of Clinical Toxicology; Imam Reza Hospital, Faculty of Medicine Mashhad University of Medical Sciences, Mashhad, IR, Iran
- Frank Balszuweit** Bundeswehr Medical Service Headquarters, Koblenz, Germany
- Atrayee Banerjee** Senior Toxicologist, Reckitt Benckiser, United States
- Cheryl B. Bast** Keller and Heckman LLP, Washington, DC, United States
- Daria Belinskaia** Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, Saint Petersburg, Russia
- Vijay K. Bharti** Defence Institute of High Altitude Research (DIHAR), DRDO, Ministry of Defence, Leh-Ladakh, India
- Claire E. Bollinger** College of Health & Rehabilitative Sciences, The Ohio State University, Columbus, OH, United States
- Robert P. Casillas** Latham BioPharm Group, Cambridge, MA, United States
- Ryan Clark** *Office for Educational Outreach and Health Careers*, Morehouse School of Medicine, Atlanta, GA, United States
- Edward D. Clarkson** Medical Toxicology Branch, Analytical Toxicology Division, US Army Medical Research Institute of Chemical Defense, Aberdeen Proving Grounds - Edgewood Area, MD, United States
- Toby B. Cole** Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA, United States; Center on Human Development and Disability, University of Washington, Seattle, WA, United States
- Rhian B. Cope** Australian Pesticides and Veterinary Medicines Authority, Canberra, Australia
- Robert W. Coppock** Toxicologist and Associates, Ltd, Vegreville, AB, Canada
- Lucio G. Costa** Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA, United States; Department of Medicine and Surgery, University of Parma, Parma, Italy
- Wolf-D. Dettbarn** Vanderbilt University, Nashville, TN, United States
- Alzbeta Dlabkova** Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defense, Hradec Kralove, Czech Republic
- Robin B. Doss** Toxicology Department, Breathitt Veterinary Center, Murray State University, Hopkinsville, KY, United States
- Margitta M. Dziwenka** Health Sciences Laboratory Animal Services (HSLAS), Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada; ToxAlta Consulting, Vegreville, AB, Canada
- Jorge Estevez** University Miguel Hernandez of Elche, Elche, Spain
- Tim J. Evans** Veterinary Medical Diagnostic Laboratory, Department of Veterinary Pathobiology, University of Missouri, Columbia, MO, United States
- John K. Fink** Department of Neurology, University of Michigan, Ann Arbor, MI, United States

- Swaran J.S. Flora** National Institute of Pharmaceutical Education and Research-Raebareli, Transit Campus, Lucknow, India
- Clement E. Furlong** Department of Medicine (Division of Medical Genetics), University of Washington, Seattle, WA, United States; Department of Genome Sciences, University of Washington, Seattle, WA, United States
- Josef Fusek** Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defense, Hradec Kralove, Czech Republic; Faculty of Health Studies, University of Pardubice, Pardubice, Czech Republic
- Jacqueline Garrick** Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA, United States
- Jeffery M. Gearhart** The Henry M. Jackson Foundation for Military Medicine, 711th HPW, Airman Readiness Optimization Branch, Wright-Patterson AFB, Dayton, OH, United States
- Donald R. Gerecke** Department of Pharmacology and Toxicology, Rutgers University, Piscataway, NJ, United States
- Dana F. Glass-Mattie** Oak Ridge National Laboratory, Oak Ridge, TN, United States
- Saryu Goel** Expert Consultants, Leesburg, VA, United States
- Nikolay Goncharov** Research Institute of Hygiene, Occupational Pathology and Human Ecology, Saint Petersburg, Russia; Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, Saint Petersburg, Russia
- Richard K. Gordon** US Army Medical Research and Materiel Command, Ft. Detrick, MD, United States
- Joshua P. Gray** Department of Science. US Coast Guard Academy, New London, CT, United States
- Zoran Grubic** Laboratory for Molecular Neurobiology, Institute of Pathophysiology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- Kavita Gulati** Department of Pharmacology, Vallabhbai Patel Chest Institute, University of Delhi, New Delhi, India
- Ramesh C. Gupta** Toxicology Department, Brethitt Veterinary Center, Murray State University, Hopkinsville, KY, United States; Division of Pharmacology & Toxicology, IVRI, Bareilly, Uttar Pradesh, India
- Sharon M. Gwaltney-Brant** Veterinary Information Network, Davis, CA, United States
- Tracey A. Hamilton** Department of Toxicology, US Army Medical Research Institute of Chemical Defense, MD, United States
- Kenneth J. Harris** Department of Neuroscience and Pharmacology, Meharry Medical College, Nashville, TN, United States
- Darryl B. Hood** Division of Environmental Health Sciences, College of Public Health, The Ohio State University, Columbus, OH, United States
- Edward M. Jakubowski** Toxicology and Obscurants Division, Combat Capabilities Development Command-Chemical Biological Center, Aberdeen Proving Ground, MD, United States
- Richard Jenkins** School of Allied Health Sciences, De Montfort University, Leicester, United Kingdom
- David A. Jett** National Institutes of Health/National Institute of Neurological Disorders and Stroke, Rockville, MD, United States
- Yuqin Jiao** Department of Neuroscience, Colorado State University, Fort Collins, CO, United States
- Harald John** Bundeswehr Institute of Pharmacology and Toxicology, Munich, Germany
- Nathan H. Johnson** Department of Laboratory Sciences, University of Arkansas for Medical Sciences, AR, United States
- Milan Jokanović** Experta Consulting, Belgrade, Serbia
- Daniel Jun** Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defense, Hradec Kralove, Czech Republic; Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defense in Brno, Trebesska, Czech Republic; University Hospital Hradec Kralove, Sokolska, Czech Republic
- Georgy Karakashev** Research Institute of Hygiene, Occupational Pathology and Human Ecology, Saint Petersburg, Russia
- Jiri Kassa** Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defense, Hradec Kralove, Czech Republic; Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defense in Brno, Trebesska, Czech Republic
- Maja Katalinic** Institute for Medical Research and Occupational Health, Zagreb, Croatia
- Kai Kehe** Bundeswehr Medical Service Academy, Division F, Medical CBRN Defense, Munich, Germany

- Natalia Khlebnikova** Research Institute of Hygiene, Occupational Pathology and Human Ecology, Saint Petersburg, Russia
- Urmila P. Kodavanti** Public Health and Integrated Toxicology Division, Center for Public Health and Environmental Assessment, US Environmental Protection Agency, Research Triangle Park, NC, United States
- Ekaterina Korf** Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, Saint Petersburg, Russia
- Nadezhda Koryagina** Research Institute of Hygiene, Occupational Pathology and Human Ecology, Saint Petersburg, Russia
- Bojan Kovač** Military Medical Academy, Belgrade, Serbia
- Gopala Krishna** Expert Consultants, Ellicott City, MD, United States
- Mayur Krishna** Expert Consultants, Ellicott City, MD, United States
- Kamil Kuca** Philosophical Faculty, University of Hradec Kralove, Hradec Kralove, Czech Republic; Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
- Dinesh Kumar** FJD-R, IVRI, Rajdhani Enclave, Dehradun, Uttarakhand, India
- Yukio Kuroiwa** Japan Poison Information Centre, Tsukuba, Japan
- Sergey Kuznetsov** Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, Saint Petersburg, Russia
- Kamil Kuča** University Hospital Hradec Kralove, Sokolska, Czech Republic; Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanskeho, Czech Republic; Faculty of Science and Philosophical, University of Hradec Kralove, Hradec Kralove, Czech Republic
- Joseph C. Larsen** Strategic Portfolio Development, VenatoRx Pharmaceuticals, PA, United States
- Mikhail Leninskiy** Research Institute of Hygiene, Occupational Pathology and Human Ecology, Saint Petersburg, Russia
- Jing Liu** Preclinical Safety Assessment, Charles River Laboratories, Inc. Reno, NV, United States; Department of Physiological Sciences, College of Veterinary Medicine, Oklahoma State University, Stillwater, OK, United State
- Heather Lochotzki** Division of Environmental Health Sciences, College of Public Health, The Ohio State University, Columbus, OH, United States
- Oksana Lockridge** University of Nebraska Medical Center, Eppley Institute, Omaha, NE, United States
- Jordana Lockwich** Department of Physical Therapy, University of Evansville, IN, United States
- Bommanna G. Loganathan** Department of Chemistry and Watershed Studies Institute, Murray State University, Murray, KY, United States
- Dragana Lončar-Stojiljković** Department of Anesthesiology and Intensive Care, Institute for Cardiovascular Diseases, Dedinje, Belgrade, Serbia
- Sofya V. Lushchekina** Emanuel Institute of Biochemical Physics of Russian Academy of Sciences, Moscow, Russian Federation
- Megan E. Lyman** Department of Toxicology, US Army Medical Research Institute of Chemical Defense, MD, United States
- Mark Maguire** Department of Neuroscience and Pharmacology, Meharry Medical School, Nashville, TN, United States
- Galina F. Makhaeva** Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, Russia
- Jitendra K. Malik** FJD-R, IVRI, Rajdhani Enclave, Dehradun, Uttarakhand, India
- David Malinak** University of Hradec Kralove, Faculty of Science, Department of Chemistry, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republic
- Tomaz Mars** Laboratory for Molecular Neurobiology, Institute of Pathophysiology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- Judit Marsillach** Department of Medicine (Division of Medical Genetics), University of Washington, Seattle, WA, United States
- María-Rosa Martínez-Larrañaga** Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Complutense University of Madrid, Madrid, Spain
- Patrick Masson** Neuropharmacology Laboratory, Kazan Federal University, Kazan, Russian Federation
- Shigeki Masunaga** Yokohama National University, Yokohama, Japan
- Monique McCallister** Cooperative Extension Program, Tennessee State University, Nashville, TN, United States

- Linda A. McCauley** Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA, United States
- Roger O. McClellan** Toxicology and Human Health Risk Analysis, Albuquerque, NM, United States
- Patrick M. McNutt** Department of Toxicology, US Army Medical Research Institute of Chemical Defense, MD, United States
- Edward C. Meek** Center for Environmental Health Sciences, College of Veterinary Medicine, Mississippi State University, MS, United States
- Elaine Merrill** Air Force Research Laboratory, 711/HPW RHBBF, Wright-Patterson AFB, OH, United States
- Sylvia Milanez** Oak Ridge National Laboratory, Oak Ridge, TN, United States
- Igor Mindukshev** Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, Saint Petersburg, Russia
- Katarina Mis** Laboratory for Molecular Neurobiology, Institute of Pathophysiology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- Jan Misik** Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defense, Hradec Kralove, Czech Republic; Biomedical Research Centre, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- Michael J. Murphy** University of Minnesota, St. Croix Trail N, Stillwater, MN, United States
- Kamil Musilek** University of Hradec Kralove, Faculty of Science, Department of Chemistry, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republic
- Tamie Nakajima** Department of Life and Health Sciences, Chubu University, Kasugai, Japan
- Marian R. Nelson** Department of Toxicology, US Army Medical Research Institute of Chemical Defense, MD, United States
- Eugenie Nepovimova** Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
- Tetsu Okumura** Japan Poison Information Centre, Tsukuba, Japan
- Jiri Patočka** Department of Radiology and Toxicology, Faculty of Health and Social Studies, University of South Bohemia Ceske Budejovice, Hradec Kralove, Czech Republic
- Katarina Pegan** Laboratory for Molecular Neurobiology, Institute of Pathophysiology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- Jaroslav Pejchal** Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic
- Sergej Pirkmajer** Laboratory for Molecular Neurobiology, Institute of Pathophysiology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- René Pita** Chemical Defense Department, Army CBRN Defense School, Madrid, Spain
- Jason Pitt** Department of Physical Therapy, University of Evansville, Evansville, IN, United States
- Yiuka Pitt** Department of Anesthesia, Methodist Health, KY, United States
- Gennady E. Platoff, Jr.** National Institutes of Health/ National Institute of Allergy and Infectious Diseases, Rockville, MD, United States
- Carey N. Pope** Department of Physiological Sciences, College of Veterinary Medicine, Oklahoma State University, Stillwater, OK, United State
- Andrey Radilov** Research Institute of Hygiene, Occupational Pathology and Human Ecology, Saint Petersburg, Russia
- Anu Rahal** Division of Animal Health, ICAR-Central Institute for Research on Goats, Mathura, India
- Aramandla Ramesh** Department of Biochemistry and Cancer Biology, Meharry Medical College, Nashville, TN, United States
- Arunabha Ray** Department of Pharmacology, Hamdard Institute of Medical Sciences and Research (HIMSR), Hamdard University, New Delhi, India
- Vladimir Rembovskiy** Research Institute of Hygiene, Occupational Pathology and Human Ecology, Saint Petersburg, Russia
- Raina Rhoades** Department of Neuroscience and Pharmacology, Meharry Medical College, Nashville, TN, United States
- Rudy J. Richardson** Department of Environmental Health Sciences, Department of Neurology, Center of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, United States
- Dragana Ristić** Military Medical Academy, Belgrade, Serbia
- Peter J. Robinson** The Henry M. Jackson Foundation for Military Medicine, Air Force Research Laboratory, 711/HPW RHBBF, Wright-Patterson AFB, Dayton, OH, United States
- Alejandro Romero** Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Complutense University of Madrid, Madrid, Spain

- Chris Ruark** The Procter and Gamble Company, Mason, OH, United States
- Harry Salem** Columbus, OH, United States
- Natalia Samchenko** Research Institute of Hygiene, Occupational Pathology and Human Ecology, Saint Petersburg, Russia
- Tetsuo Satoh** Japan Poison Information Centre, Tsukuba, Japan
- Russell E. Savage** Toxicology Education Foundation, Cincinnati, OH, United States
- Elena Savelieva** Research Institute of Hygiene, Occupational Pathology and Human Ecology, Saint Petersburg, Russia
- Lawrence M. Schopfer** University of Nebraska Medical Center, Eppley Institute, Omaha, NE, United States
- Alfred M. Sciuto** (Retired), Biochemical and Physiology Branch, Analytical Toxicology Research Division, US Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD, United States
- Yasuo Seto** RIKEN SPring-8 Center, Hyogo, Japan
- Michael P. Shakarjian** Environmental Health Science, New York Medical College, School of Health, Sciences and Practice, Valhalla, NY, United States
- Vladimir Shmurak** Research Institute of Hygiene, Occupational Pathology and Human Ecology, Saint Petersburg, Russia; Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, Saint Petersburg, Russia
- Adam Skarka** University of Hradec Kralove, Faculty of Science, Department of Chemistry, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republic
- Ranko Škrbić** Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Banja Luka, Banja Luka, Republic of Srpska, Bosnia and Herzegovina
- Miguel Sogorb** University Miguel Hernandez of Elche, Elche, Spain
- Shardell M. Spriggs** National Institutes of Health/ National Institute of Neurological Disorders and Stroke, Rockville, MD, United States
- Sakshi Srivastava** National Institute of Pharmaceutical Education and Research-Raebareli, Transit Campus, Lucknow, India
- Dirk Steinritz** Bundeswehr Medical Service Academy, Division F, Medical CBRN Defense, Munich, Germany
- Miloš P. Stojiljković** Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Banja Luka, Banja Luka, Republic of Srpska, Bosnia and Herzegovina
- Neera Tewari-Singh** Department of Pharmacology & Toxicology, Michigan State University, East Lansing, MI, United States
- Horst Thiermann** Bundeswehr Institute of Pharmacology and Toxicology, Munich, Germany
- Suresh Kumar Thokchom** Department of Pharmacology, Vallabhbhai Patel Chest Institute, University of Delhi, New Delhi, India
- Larry J. Thompson** Thompson Tox, Edwardsville, IL, United States
- Anton Ukolov** Research Institute of Hygiene, Occupational Pathology and Human Ecology, Saint Petersburg, Russia
- Luis G. Valerio** Toxicology Expert, Ellicott City, MD, United States
- M.J. van der Schans** TNO, Rijswijk, The Netherlands
- Daya R. Varma** Montreal, Canada
- Eugenio Vilanova** University Miguel Hernandez of Elche, Elche, Spain
- Annetta Watson** Environmental Sciences Division, Oak Ridge National Laboratory, Oak Ridge, TN, United States
- Sanjeeva J. Wijeyesakere** Department of Environmental Health Sciences, Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, United States
- Tina Wismer** ASPCA Animal Poison Control Center, Urbana, IL, United States
- R. Mark Worden** Department of Biomedical Engineering, Department of Chemical Engineering and Materials Science, Michigan State University, East Lansing, MI, United States
- Franz Worek** Bundeswehr Institute of Pharmacology and Toxicology, Munich, Germany
- Linzzi K. Wright** CDC Chemical Biological Center, Aberdeen Proving Ground, MD, United States
- Hidegori Yamasue** Department of Psychiatry, Hamamatsu University School of Medicine, Hamamatsu city, Japan
- Takemi Yoshida** Japan Poison Information Centre, Tsukuba, Japan
- Toshiharu Yoshioka** Japan Poison Information Centre, Tsukuba, Japan

Robert A. Young Senior Research Staff (Retired),
Environmental Sciences Division, Oak Ridge National
Laboratory, Oak Ridge, TN, United States

Snjezana Zaja-Milatovic PAREXEL International,
Alexandria, VA, United States; PAREXEL
International, Billerica, MA, United States

Valeriy Zinchenko Institute of Cell Biophysics, Russian
Academy of Sciences, Pushchino, Russia

Csaba K. Zoltani Emeritus, ARL, Aberdeen Proving
Ground, MD, United States

Introduction

Extremely toxic chemicals have been used for thousands of years in wars, conflicts, and extremist activities by terrorists and dictators in malicious poisonings and executions. One of the earliest forms of chemical warfare agents (CWAs) was natural toxins from plants or animals, which were used to coat arrowheads, commonly referred to as “arrow poisons.” Ancient use of some CWAs and riot control agents (RCAs) dates back to the 5th century BCE during the Peloponnesian War, when the Spartans used smoke from burning coal, sulfur, and pitch to temporarily incapacitate and confuse occupants of Athenian strongholds. The Spartans also used bombs made of sulfur and pitch to overcome the enemy. The Romans used irritant clouds to drive out adversaries from hidden dwellings. In the 15th century, Leonardo da Vinci proposed the use of a powder of arsenic sulfide as a chemical weapon.

Modern use of CWAs and RCAs or incapacitating agents dates back to World War I (WWI). With advancements in science and chemistry in the 19th century, the possibility of chemical warfare increased tremendously. The first full-scale use of CWAs began in April 1915 when German troops launched a poison gas attack at Ypres, Belgium, using 168 tons of chlorine gas, killing about 5000 Allied (British, French, and Canadian) soldiers. During WWI, the deployment of CWAs, including toxic gases (chlorine, phosgene, cyanide, and mustard), irritants, and vesicants in massive quantities (about 125,000 tons), resulted in about 90,000 fatalities and 1.3 million nonfatal casualties. The majority of deaths in WWI were a result of exposure to chlorine and phosgene gases. During the Holocaust, the Nazis used carbon monoxide and the insecticide Zyklon-B, containing hydrogen cyanide, to kill several million people in extermination camps. Poison gases were also used during the Warsaw Ghetto Uprising in 1943. Again, in November 1978, religious cult leader Jim Jones murdered over 900 men, women, and children with cyanide.

Prior to, during, and after World War II, anticholinesterase organophosphate (OP) nerve agents/gases were developed in Germany, the United States, the United Kingdom, and Russia, and were produced in large volumes in many other countries. They were maximally produced and stockpiled during the “Cold War” period.

These nerve agents have been used in wars and by dictators, extremists, cult leaders, and terrorist groups as chemical weapons of mass destruction (CWMD) on many occasions. In 1980, Iraq attacked Iran, employing mustard and OP nerve gases. During the period of the Iraq and Iran conflict (1980–88), Iran sustained 387 attacks and more than 100,000 troops were victims along with a large number of civilians. Thousands of these victims still suffer from long-term health effects. Shortly after the end of the Iraq–Iran war in 1988, the brutal dictator of the Iraqi regime, Saddam Hussein, used multiple CWAs against the Kurdish minorities in Halabja, killing more than 10% of the town’s 50,000 residents. To date, mustards have been used in more than a dozen conflicts, killing and inflicting severe injuries in millions of military personnel and civilians.

During the Persian Gulf War, exposure to OP nerve agents occurred from the destruction of munitions containing 8.5 metric tons of sarin/cyclosarin housed in Bunker 73 at Khamisyah on March 4, 1991, and additional destruction of these nerve agents contained in rockets in a pit at Khamisyah on March 10, 1991. Although exposure levels to nerve agents were too low to produce signs of acute toxicity, military personnel serving in and around the Khamisyah area still suffer from long-term adverse health effects, most notably “Gulf War syndrome.” In 1996, about 60,000 veterans of the Persian Gulf War claimed to suffer from “Gulf War syndrome” or “Gulf veterans’ illnesses,” possibly due to low-level exposure of nerve agents, mustard, pyridostigmine bromide, and pesticides. Exposed veterans had an increased incidence of chronic myelocytic leukemia and increased risk of brain cancer deaths compared to unexposed personnel.

In the mid-1990s, two terrorist attacks by a fanatic religious cult, Aum Shinrikyo (Supreme Truth), known as Aleph since 2000, took place in Japan (Matsumoto, 1994 and Tokyo subway, 1995). In both incidents, the OP nerve agent sarin was used as a CWA. Aum Shinrikyo in Kamikuishiki, Japan, manufactured an estimated 70 tons of sarin. Although the total fatality count involved not more than 20 civilians, injuries were observed in more than 6000 and millions were terrified. These acts of chemical terrorism were unprecedented and the impact

propagated throughout not only Japan, but the entire world. In the past few decades, many incidents have also occurred with biotoxins such as ricin and anthrax. Publicity surrounding frequent recent use due to easy access and copycat crimes increase the possibility of future use of these chemicals and biotoxins, which warrants advancement in emergency preparedness planning at the federal, state, and local government levels.

It is interesting to note that toxic chemicals have been used by governmental authorities against rebels, or civilians. In the 1920s, Britain used chemical weapons in Iraq “as an experiment” against Kurdish rebels seeking independence. Winston Churchill strongly justified the use of “poisoned gas against uncivilized tribes.” The Russian OSNAZ forces used an aerosol containing fentanyl anesthetic during the Moscow theater hostage crisis in 2002. RCAs were frequently used in the US in the 1960s to disperse crowds in riot control.

Intoxications or deaths by poisoning of emperors, heads of countries, and other significant individuals have been recorded for a long time. The French Emperor Napoleon Bonaparte was poisoned with a mixture of heavy metals including arsenic and mercury. Napoleon Bonaparte died on May 5, 1821, while he was in exile on the island of St. Helena. In December 2004, during the presidential campaign, the former President of Ukraine, Viktor Yuschenko, was poisoned by a very high dose of 2,3,7,8-tetrachlorodibenzodioxin (TCDD). Ex-lieutenant of the Russian Federal Service, Alexander Litvinenko (1962–2006) died on November 23, 2006, from intoxication with polonium 210. Kim Jong-Nam, a half-brother of North Korean dictator Kim Jong-Un was poisoned with VX nerve agent at Kuala Lumpur airport in Malaysia. He died within 20 min of exposure. On March 4, 2018, the former officer of the Russian Main Intelligence Directorate, Sergey Skripal, and his daughter, Yuliya Skripal, were poisoned with Novichoks in Salisbury, United Kingdom. Following an aggressive antidotal therapy, fortunately both survived.

At present, more than 25 countries and possibly many terrorist groups possess CWAs, while many other countries and terrorist groups are seeking to obtain them, due to their easy access. Some of these agents are stockpiled in enormous quantities and their destruction and remediation are not only expensive but also associated with significant health risks. There is also the possibility of accidental release of CWAs or CWMD at their production sites, as well as during transportation, dissemination, and deployment. The intentional or accidental release of highly toxic chemicals, such as the nerve agent VX (Dugway Proving Ground, Utah, 1968), Agent Orange (Vietnam, 1961–72), PBB (Michigan, USA, 1973), dioxin (Seveso, Italy, 1976), and methyl isocyanate (Bhopal, India, 1984), has caused injuries to more than a

million people, and deaths in several thousands. A 1968 accident with VX nerve gas killed more than 6000 sheep in the Skull Valley area of Utah.

After September 11, 2001, the chances are greater than ever before of the use of CWMD by extremist and terrorist groups like Al Qaeda, which presents great risks to humans, domestic animals, and wildlife in many parts of the world. On November 26, 2008, Pakistani Islamic terrorists attacked Mumbai city in India at 10 different sites, including two luxury hotels, a Jewish center, a train station, and hospitals and cafes. Approximately 200 innocent people died and about 300 people were injured by bullets and smoke. It is more likely that these terrorist groups may use toxic industrial chemicals (agents of opportunity) either as such or as a precursor for more deadly CWMD. At present, many countries have established Defense Research Institutes with two major missions: (1) to understand the toxicity profile of CWAs/CWMDs and (2) to develop strategic plans for prophylactic and therapeutic countermeasures. By the turn of the 21st century, the US established the Department of Homeland Security. Many other countries also developed similar governing branches and agencies at the state and national levels to protect people and property from terrorist attacks. Among chemical, biological, and radiological weapons, the possibility of CWMD is more likely because of their easy access and delivery system. It is important to mention that understanding the toxicity profile of CWAs/CWMD is very complex, as these chemical compounds are of a diverse nature, and, as a result, treatment becomes very difficult or in some cases impossible.

In the past, many accords, agreements, declarations, documents, protocols, and treaties have been signed at the international level to prohibit the development, production, stockpiling, deployment, and use of CWAs, yet dictators and terrorists produce and/or procure these chemicals to harm or kill enemies, create havoc, and draw national and international attention. In 1907, The Hague Convention outlawed the use of chemical weapons, yet during WWI, many countries used these chemicals. The first international accord on the banning of chemical warfare was agreed upon in Geneva in 1925. Despite the General Protocol, the Japanese used chemical warfare against China in 1930. In 1933, the Chemical Weapon Convention banned the development, possession, and use of CWAs. The document was signed and implemented by more than 100 countries. Yet, during WWI many chemicals of warfare were developed, produced, and used by several countries. In 1993, another global convention banning the production and stockpiling of CWAs was signed by over 100 countries.

The delayed health effects from CWAs used in the Iraq–Iran conflict of the 1980s, sarin subway attacks in Japan, and the First Gulf War in the 1990s are still not

well understood. Recently, the Syrian government stockpiled over 1300 metric tons of chemical agents, including sarin, VX, and sulfur mustard. In August 2013, the Syrian military repeatedly attacked civilians with chemical weapons, including sarin and chlorine. More than 1300 people died and thousands were injured. Again, on April 11–13, 2014, Syrian military forces attacked civilians in Hama province with chlorine gas, killing and injuring an unaccounted number of people. Despite warnings from many countries, the Syrian army continues to use CWAs against civilians. In the present world situation, it is highly likely that these agents will be used in wars, conflicts, terrorist attacks, and with malicious intent. In such scenarios, these extremely toxic agents continuously pose serious threats to humans, animals, and wildlife.

The first edition of this *Handbook of Toxicology of Chemical Warfare Agents* was prepared in 2009 in order to offer the most comprehensive coverage of every aspect of the deadly toxic chemicals that can be used as CWAs/CWMD. Since the publication of the first edition of this *Handbook*, concerns over the use and misuse of CWAs and BWAs have become greater than ever before. The second edition of the *Handbook of Toxicology of Chemical Warfare Agents* was published in 2015. This third edition of this *Handbook* is prepared to meet the current challenges facing academicians and lay persons alike. The format employed is user friendly and easy to understand. Standalone chapters on individual chemical and a few biological agents, target organ toxicity, biosensors and biomarkers, risks to man, animals, and wildlife, and prophylactic and therapeutic countermeasures are just a

few of the many novel topics covered in this volume. The chapters are enriched with historical background as well as the latest information and up-to-date references. With 73 chapters, this book will serve as a reference source for biologists, toxicologists, pharmacologists, forensic scientists, analytical chemists, local/state/federal officials in the Department of Homeland Security, Department of Defense, Defense Research Establishments, Department of Veterans Affairs, physicians at medical and veterinary emergency care units of hospitals, poison control centers, medical and veterinary diagnostic labs, environmentalists and wildlife interest groups, researchers in the area of nuclear, chemical, and biological warfare agents, and college and university libraries.

Contributors of the chapters in this book are the most qualified scientists in their particular areas of chemical and biological warfare agents and radiation. These scientists are from around the globe and are regarded as authorities in the fields of pharmacology, toxicology, and military medicine. The editor sincerely appreciates each author for his/her dedicated hard work and invaluable contributions to this volume. The editor gratefully acknowledges Robin B. Doss and Denise M. Gupta for their technical assistance. Finally, the editor remains indebted to the editors at Elsevier (Kristi Anderson, Kattie Washington, and Kiruthika Govindaraju) for their immense contributions to this book.

Ramesh C. Gupta

*Toxicology Department, Breathitt Veterinary Center,
Murray State University, Hopkinsville, KY, United States*

History of toxicology: from killers to healers

Eugenie Nepovimova¹ and Kamil Kuca²

¹Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic, ²Philosophical Faculty, University of Hradec Kralove, Hradec Kralove, Czech Republic

1.1 Introduction

The word *toxicology* comes from the Greek words *toxicon*, meaning a poison, and *logos*, meaning a scientific study. Today, the term *toxicology* refers to a scientific discipline dealing with the physical-chemical properties of toxic substances, their mechanisms of action on the body, clinical symptoms of intoxications, and the prevention and treatment of various poisonings (Klaassen, 2018). It would not be an exaggeration to claim that toxicology is almost as old as mankind. The earliest mentions of toxic substances and intoxications can be found not only in ancient scientific literature, but also in Greek myths. For example, Homer describes how Odysseus sent a warrior to Egypt to bring back traditional Egyptian poisons used for arms ammunition. In another legend, Hercules soaked his weapons in poison of the sacred Lernean hydra. Last, but not least, the myth of Helen of Troy tells how her captor died because of a wound caused by a poisoned arrow.

1.2 Ancient times

Among the oldest literary sources focused on toxicology is the Ebers Papyrus (1550 BCE) (Fig. 1.1), found in 1872 in Thebes. This 20.5 m long scroll, glued from 108 smaller sheets of papyrus, is also called “The book of preparation of remedies for all parts of the body.” The oldest pharmacopoeia of the ancient Egyptians contains more than 900 prescriptions for drugs for the treatment of diseases associated with the gastrointestinal tract, respiratory tract, ear, throat, nose, eye, and skin. Such prescriptions involved substances like opium, arsenic trioxide, aconitine, cyanogenic glycosides, or a herb called

Dia-Dia, currently known as mandrake (*Mandragora officinalis*, *Solanaceae*) (Hallmann-Mikołajczak, 2004). Ancient Egyptian surgeons used the juice of mandrake root for anesthesia and analgesia. Later, the art of the preparation of hypnotic and painkilling remedies isolated from the mandrake root transferred from Egypt to ancient Greece. During surgical operations, the Greeks used a sponge soaked in mandrake hot juice for anesthesia. Inhalation of the vapors of this juice resulted in a deep sleep of the patient. In the works of the Roman physician Galen, we can find passages telling about large quantities of mandrake tincture that were delivered daily to Rome. Apart from the medicinal use of mandrake, one of the Roman writers mentions mandrake wine used for war purposes, thanks to which the Carthaginians defeated the enemy. The soldiers of ancient Carthage left their camp with the mandrake wine in a conspicuous place. After returning back to the camp, they thereafter easily overpowered their sleeping enemies (Emboden, 1989; Mion, 2017).

Probably the most famous poisoning of the Hellenistic period was the execution of the Greek philosopher Socrates (470–399 BCE), who was condemned to drink the extract from hemlock (*Conium maculatum*, *Apiaceae*). His death is depicted in detail in Plato’s tract *Phaedo* (Hotti and Rischer, 2017; Nepovimova and Kuca, 2019). The description of poisoning corresponds exactly to the present knowledge of coniine, the main component of hemlock.

The period of ancient Greece in world history is known for the flourishing of various scientific disciplines, including medicine. The founder of the most famous school of medicine, that was located in the Greek town of Kos, was the so-called “Father of Medicine” Hippocrates



FIGURE 1.1 Ebers Papyrus found in 1872 in Thebes (https://commons.wikimedia.org/wiki/File:A_page_from_the_Ebers_Papyrus,_written_circa_1500_B.C._Wellcome_M0008455.jpg).

(460–370 BCE) (Fig. 1.2). Hippocrates rejected using poisons for removing unwanted persons. Therefore in his works, toxic substances are rarely mentioned. Some of his disciples, such as Pliny or Galen, followed the same principle, describing in their works only the antidotes. Such an informal rule has been preserved until the modern era, when young doctors, by taking the Hippocratic Oath, promise neither to administer a poison to anybody when asked to do so, nor to suggest such a course (Emery, 2013).

The ancient scientists abounded in a deep knowledge of various poisons. Usually they gained such knowledge from the observation of accidental poisonings, as well as from intentional exposure to poisons. In contrast to Eastern countries, in ancient Greece and subsequently Rome, toxic substances were quite often used as a means of killing convicts. Thus the ancient Greek poet and physician Nikander of Kolophon in his poem *Theriaca* describes clinical symptoms of intoxications by various animal toxins. In Nikander's further work *Alexipharmaca* that has survived to the present time, we find descriptions of the characteristics of plant poisons as well as methods for their treatment. As very effective therapeutic approaches he recommended invoking vomiting by drinking warm flaxseed oil or irritating the throat by simple devices made from paper or bird feathers. The majority of the knowledge reported by Nikander was based on his own experiments on convicted criminals. In addition,




FIGURE 1.2 Father of Medicine, Hippocrates (https://commons.wikimedia.org/wiki/File:A_marble_bust_said_to_represent_Hippocrates_by_J._Faber._Wellcome_M0017663.jpg).

Nikander was by all accounts the first to describe the signs of lead poisoning (Clauss, 2012). In ancient Rome, lead was widely used in everyday life. For example, lead plates were added to wine to improve its quality. At that time, lead was very expensive and only rich people could afford it. Therefore it is not surprising that chronic lead poisoning became a scourge of the ancient Roman aristocracy (Hernberg, 2000).

From the point of view of the history of toxicology as a medical discipline, not only were poisoners and crimes committed by means of poisons important, but also searching for potent antidotes. Especially in ancient times, there was an obsession to discover a universal antidote, able to protect against most, if not all, poisons. Quite instructive is the story of King Mithridates VI of Pontus (132–63 BCE) (Fig. 1.3). Mithridates was terribly afraid of poisons, therefore, he began to study toxicology in depth—he observed the effects of various poisons on people (mostly convicts or slaves), designed antidotes, and subsequently tested their efficacy on the same groups of people. Finally, he managed to prepare a universal antidote consisting of 36 components. Such



FIGURE 1.3 King Mithridates VI of Pontus (https://commons.wikimedia.org/wiki/File:Mithridates_VI_Louvre_white_background.jpg).

an antidote even received a special designation in the Roman Pharmacopoeia—*mithridaticum*. The reputation of this antidote was excellent. It was even considered the best antidote of those times, capable of preventing the actions of aconitine, snake, scorpion, or spider toxins, etc. King Mithridates believed in his recipe so much that he decided to take this remedy daily. Acquired resistance, however, played a crucial role in his life. In old age, Mithridates attempted to commit suicide by taking a large dose of poison, but survived. Therefore he was forced to use other means (a sword) to finish this act. Based on this legend, the term *mithridatism* has been adopted into the modern toxicology indicating the increased resistance of an individual to poisons (Griffin, 1995; Valle et al., 2012, 2009).

The last wife of the Roman Emperor Claudius (10 BCE–CE 54) was his niece Agrippina the Younger (CE 15–59) (Fig. 1.4). Soon after their marriage, she decided to get rid of her husband as well as his first-born son Britannicus to make her own son, Nero, the emperor (Aveline, 2004). First, she poisoned Claudius using the toxin muscarine present in toxic mushrooms, fly agaric (*Amanita muscaria*, *Amanitaceae*), in one of his meals. The Emperor's physician, Aesculapius, tried to evoke vomiting in Claudius. However, Agrippina foresaw such a turn of events and had prepared in advance a poisoned

feather. This feather was in all probability the product of the famous ancient poisoner—Locusta (Marmion and Wiedemann, 2002). After Claudius' death, Nero (CE 37–68) (Fig. 1.4) became the Emperor of Rome. Despite this, Nero's stepbrother Britannicus still constituted a threat to him (Shotter, 2008). Similarly to his mother Agrippina, Nero also asked for the help of the poisoner Locusta. In this case, she gave him a poison that was added to Britannicus' wine. After removal of his competitor, 17-year-old Nero became the only possible Emperor of Rome. Thus he decided to reward Locusta by an extraordinary right—to educate her own students. This story was one of many examples in world history where poisons were used for criminal purposes. Therefore in 81 BCE, the Roman dictator Sulla was forced to pass a special law ordering punishment, including the death penalty, for those who used poisonous substances with criminal intent (Telford, 2014).

Dioscorides (CE 40–90), the physician of the Roman Emperor Nero, in his tract *De Materia Medica* (Fig. 1.5) classified poisons based on their origin to plant, animal, and mineral. Additionally, in *De Materia Medica* we may find the methods of identification of several poisons. Such identification occurred in the scientific literature for the first time. For the next 15 centuries, Dioscorides' work was considered the “Holy Bible” of toxicology (Staub et al., 2016).

1.3 The Middle Ages

In medieval Europe, poisons were freely available in pharmacies. The first attempt to stop such a trade in poisons was made in Italy. In 1365 in Siena, apothecaries were forbidden from selling arsenic and mercury to people unknown to them. In France, a ban on toxic substances was issued in 1662, whereas in Russia this took place only in 1773 (Nepovimova and Kuca, 2019). Despite these restrictions, the question of searching for novel more potent poisons and corresponding antidotes remained relevant.

In Europe, the search for novel antidotes as well as their use in the prevention and treatment of poisoning continued until the beginning of the 18th century, and in Turkey until the beginning of the 20th century. The ancient works of Galen *De Theriaca*, *ad Pisonem*, *De Usu Theriacae*, *ad Pamphilianum*, and *De Antidotis*, mainly inspired by the achievements of King Mithridates, were within the period of the Renaissance and the Middle Ages enriched with the knowledge of the Jewish physician and philosopher Moses Maimonides (1135–1204) (Fig. 1.6). His tract focused on poisons and antidotes and was published in Arabic in Cordoba (Spain) in 1198 (Rosner, 2000). This literary work constitutes a noticeable milestone in the history of toxicology, outlining the 1000-year



FIGURE 1.4 Agrippina the Younger and her son Nero (https://commons.wikimedia.org/wiki/File:Ner%C3%B3n_y_Agripina.jpg).

experience of treating various poisonings and also described the clinical picture of intoxication by poisons that were previously unknown. The first part of the tract describes intoxications as well as poisons of animal origin (bites by enraged dogs, wasps, snakes, spiders, scorpions, and other animals). As historically the first attempt, Maimonides distinguished the neurotoxic and hematotoxic symptoms of intoxication. In the second part, he focused on mineral and plant poisons. For instance, in the case of *Atropa belladonna* (*Solanaceae*) intoxication, Maimonides reported skin redness and some kind of “excitement” of the patient. As a therapeutic tool he recommended vomiting evoked by warm milk, vegetable oil, etc. (Rosner, 1968).

None of the noble families left such a significant imprint in the history of Italy and the whole world as the Spanish “holy family” of Borgia that was sadly famous for numerous murders committed by means of poisons.

These Spaniards twice occupied the throne of Saint Peter—firstly as Pope Callixtus III and subsequently as Pope Alexander VI (Hibbert, 2009). “Cantarella” was the name of the poison used by the Borgias. Allegedly, Cesare Borgia (1474–1507) (Fig. 1.7), the son of the Pope Alexander VI (1431–1503) (Fig. 1.7), received the recipe for this poison from his mother. Apparently, the mystic poison contained arsenic, salts of copper, and phosphorus. According to the literary sources, the papal alchemists prepared such toxic mixtures that a drop was enough to kill a bull. Not only the poison, but also the tools containing such poison, were unique. Cesare Borgia was the owner of a ring with a huge ruby that bore the name the “Flame of Borgia.” Several times he pronounced that this ring had repeatedly saved his life. Presumably, under the gemstone there was a skillfully made secret container with a poison. Cesare poured this poison into the drink of those who dared to encroach on



FIGURE 1.5 A page from Dioscorides' work *De Materia Medica* (https://en.wikipedia.org/wiki/De_Materia_Medica#/media/File:NaplesDioscuridesMandrake.jpg).

his life. The Pope himself also had a gold ring with a secret. In the process of shaking hands, a small thorn appeared on the inner side of the ring which slightly scratched the skin of the sentenced person and released a deadly drop of poison (Poole, 2010). Finally, destiny punished Pope Alexander VI, who accidentally drank poisoned wine that was intended for his victim (Hibbert, 2009).

Despite the wide use of poisons within the struggle for power, the development of toxicology in European countries in the Middle Ages was significantly hampered by the influence of religious ideologies. Medieval monks followed the principle "Like is cured by like" (*Similia similibus curantur*) (Zebroski, 2015). The exception was Swiss physician, alchemist, botanist, astrologer, and occultist of the era of the German Renaissance, Philippus Aureolus Theophrastus Bombastus von Hohenheim (1492–1541),

also known as Paracelsus (Fig. 1.8). He chose this pseudonym for himself and it means "more than Celsus." Aulus Cornelius Celsus was a Roman naturalist, living more than one and half thousand years before Paracelsus (Grell, 1998). Paracelsus' groundbreaking contribution to life sciences consisted mainly in the interconnection between chemistry and medicine. Therefore it is not surprising that his life credo was: "The real purpose of chemistry is not to make gold, but to make remedies!" Paracelsus has been also considered the Father of Toxicology, since in one of his books he stated: "Dose makes the poison" (*Dosis facit venenum*). Thus substances that are taken to be toxic could be harmless in small doses, whereas normally harmless substances could be fatal if consumed excessively. This postulate still belongs among the basic pillars of modern toxicology. He was also known for his revolutionary views on the observation

of nature and man, created by himself instead of simply quoting ancient texts. Last but not least, he gave the designation to the chemical element zinc and noted that certain diseases stem from the mind of the patient (Paracelsus, 1999).

With regard to poisonings, medieval Italy and later France were considered the most powerful countries in the world. The French Queen, Catherine de' Medici (1519–89) (Fig. 1.9), also known as the Queen-Poisoner, perfectly mastered the Italian technique of poisoning to achieve her intended political goals (Kruse, 2003). Alexandre Dumas, in his historical novel “Queen Margot,” wrote that Queen Catherine was involved in the death of her political rival Jeanne d’Albret by giving her an insidious present—poisoned gloves (Dumas, 1994). Within the

same novel, Dumas also describes the fatal mistake of the Queen, who at the end of her life decided to remove the son of poisoned Jeanne d’Albret—Henry. She commanded he be given a poisoned book dealing with the art of hunting. Unfortunately, this book got into the wrong hands, to her own son King Charles IX. Apart from removing the competitors within the battle for the royal throne, Queen Catherine was also known for experiments with various toxic mixtures that she conducted on poor and sick people. Catherine de' Medici carefully reported each experiment, recording the velocity of the toxic response (onset of the



FIGURE 1.6 Jewish physician and philosopher Moses Maimonides (<https://he.wikipedia.org/wiki/%D7%A7%D7%95%D7%91%D7%A5:Maimonides-2.jpg>).




FIGURE 1.8 Philippus Aureolus Theophrastus Bombastus von Hohenheim, also known as Paracelsus ([https://commons.wikimedia.org/wiki/File:Aureolus_Theophrastus_Bombastus_von_Hohenheim_\(Paracelsus\).Wellcome_V0004452.jpg](https://commons.wikimedia.org/wiki/File:Aureolus_Theophrastus_Bombastus_von_Hohenheim_(Paracelsus).Wellcome_V0004452.jpg)).



FIGURE 1.7 The Pope Alexander VI (right) and his son Cesare Borgia (left) (<https://www.flickr.com/photos/hinkelstone/38111166521>; <https://www.flickr.com/photos/eriktomer/32671151065>).



FIGURE 1.9 French Queen Catherine de' Medici (<https://commons.wikimedia.org/wiki/File:Catherine-de-medici.jpg>).

toxic effect), the efficacy of the toxic mixture, the strength of the toxic effect in various parts of the body (organ specificity, site of action), and the clinical picture of intoxication. Thus despite the poor reputation of the Queen-Poisoner, she can be considered the first experimental toxicologist in history (Whyte, 2001).

The development of industry in the 16th century gave rise to several highly specialized works dealing with occupational diseases. In 1556 Georgius Agricola (1494–1555), a German doctor and metallurgist, in his work “On Mining and Metallurgy” described severe occupational diseases of miners (Weber, 2002). The first real systematic contribution to occupational toxicology was made by Italian physician Bernardino Ramazzini (1633–1714). In his work “Diseases of the workers,” published in 1700, where he for the first time described the diseases of workers in almost 70 professions, such as miners, gilders, chemists, plasterers, blacksmiths, etc. (Dhungat, 2017).

The Golden Age of King Louis XIV of France was not associated just with the development of the country, but also with several famous cases of poisoners—Marquis de Brinvilliers, Catherine Monvoisin, and others. Catherine Monvoisin (1640–80) (Fig. 1.10) was among the most popular poison suppliers of that time. A frequent client of Madame Monvoisin was also a hot favorite of the Sun King—Marquis de Montespan. Due to the fact that poisons



FIGURE 1.10 French poisoner Catherine Monvoisin ([https://fr.wikipedia.org/wiki/Fichier:Catherine_Deshayes_\(Monvoisin,_dite_%C2%ABLa_Voisin%C2%BB\)_1680.jpg](https://fr.wikipedia.org/wiki/Fichier:Catherine_Deshayes_(Monvoisin,_dite_%C2%ABLa_Voisin%C2%BB)_1680.jpg)).

were perceived as the simplest means of solving problems among the aristocratic families, King Louis XIV issued a special law, where the definition of poison was given as: “Everything that can cause a rapid death or slowly destroy human health, regardless of the fact whether it is a simple or complex substance, must be considered as a poison.” To complete the story of French poisoners, Marquis de Brinvilliers, Catherine Monvoisin, and their associates were executed. Marquis de Montespan, a mother of eight illegitimate children of Louis XIV, was sent to exile in the Netherlands (Somerset, 2004).

In the late 17th–early 18th centuries, Neapolitan poisoner Teophania, more commonly known as Tophana, operated in Europe. Apparently, this Italian was responsible for the deaths of more than 600 people. Tophana was an inventor of an original product called *Aqua Tophana*. *Aqua Tophana* had a water-like, odorless, and colorless consistency. Allegedly, five or six drops of this magical water was enough to kill a man. The onset of the toxic effect was gradual—painless, without any sign of fever or inflammation. Death occurred due to weakness, loss of appetite, and incessant thirst. Among the most frequent customers of *Aqua Tophana* were women who desired to get rid of their husbands. The exact content of *Aqua*

Tophana remains unknown. According to one source, it was made of arsenic acid with an addition of *Herba cymbalariae* (*Scrophulariaceae*). Other sources claim that the main component of Aqua Tophana was lead acetate solution. Seniors Tophana was eventually sentenced to death and in 1709 burnt to death (Nepovimova and Kuca, 2019; Wexler, 2017).



FIGURE 1.11 The founder of toxicology Mathieu Orfila (https://commons.wikimedia.org/wiki/File:Pierre_Mathieu_Joseph_Bonaventure_Orfila._Lithograph_by_Z._Wellcome_V0004368.jpg).

At the beginning of the 19th century, the most prominent figure in toxicology was considered to be the Spanish physician Mathieu Orfila (1787–1853) (Fig. 1.11). He was the first to separate toxicology from pharmacology, clinical and forensic medicine, giving toxicology the status of an independent scientific discipline. At the age of 27, Orfila wrote a book “Treatise on poisonings,” that was later published in five editions. Several years later, another work by Orfila’s “A treatise on the remedies to be employed in cases of poisoning and apparent death: including the means of detecting poisons, of distinguishing real from apparent death, and of ascertaining the adulteration of wines” met with great interest from the scientific community. In his writings, the Spanish physician classified all known toxic substances, described the clinical picture of intoxications typical for various classes of poisons, and also recommended chemical methods for poison identification in biological matrices (Myers, 1961). Based on his works, it became obligatory to conduct a forensic chemical analysis for official confirmation of poisoning as the cause of the death. In addition, Mathieu Orfila gave the most general definition of poison that remains widely used “Poison is a substance, that by coming in contact with a living organism in a small amount, destroys its health and subsequently life” (Hadengue, 1987).

The 1850s could be characterized as the time of the formation of modern toxicology. The decisive influence belonged to the successes achieved in analytical chemistry and experimental analysis that won its place in theoretical medicine (Oser, 1987). The fundamental works of French scientists Francois Magendie (1783–1855) (Fig. 1.12) and his student Claude Bernard (1813–78) (Fig. 1.12) dealing with the mechanism of action of strychnine, cyanide, curare, carbon monoxide, and other poisons, served to strengthen the role of toxicology among the other scientific disciplines (Bloch, 1989). Numerous methods of




FIGURE 1.12 Francois Magendie (left) and his student Claude Bernard (right) (https://commons.wikimedia.org/wiki/File:Fran%C3%A7ois_Magendie._Lithograph_by_N._E._Maurin._Wellcome_V0003781.jpg; [https://commons.wikimedia.org/wiki/File:Portrait_of_Claude_Bernard_\(1813-1878\),_French_physiologist_Wellcome_M0000114.jpg](https://commons.wikimedia.org/wiki/File:Portrait_of_Claude_Bernard_(1813-1878),_French_physiologist_Wellcome_M0000114.jpg)).

particular physiological function evaluation, such as respiration and neuromuscular conduction, proposed by Claude Bernard were preserved in experimental practice for more than 100 years. Claude Bernard was also an author of the brilliant idea that toxic substances can serve as an excellent tool in physiology research. He said: “These substances could be considered as real life reagents that are carried by the blood stream to all points of the body, act on some tissues and finally lead to the death. The mechanism of death points to the physiological role of particular tissues on which they act.” This finding became a significant milestone in general physiology (Breathnach, 2014). Additionally, within his experiments with curare, Claude Bernard revealed that this poison paralyzes voluntary muscles with no effect on impulse conduction in the motor nerves as well as on contractility of the muscles. This observation led to discovery of the special sensitivity of the neuromuscular junction to curare. Several years later, these investigations served as a strong argument for the development of a theory of the neurochemical basis of excitatory transmission within the nervous system (Gomes et al., 2014).

For almost two centuries after the death of the French Emperor Napoleon Bonaparte (1769–1821) (Fig. 1.13), his demise has remained a hot topic, and the scientists continue to investigate this case. After he was sent into exile in 1820, the health status of the Corsician sharply deteriorated. Throughout his stay on the island of St. Helen, he complained about severe stomachache, weakness, and frequent attacks of nausea. Finally, on May 5, 1821, he died. According to the findings of an international group of scientists, Napoleon Bonaparte passed away due to progressive stomach cancer with metastases in the lymph nodes (Leys, 2015). However, according to conspirologists, the symptoms of the ex-Emperor’s death more resemble arsenic poisoning. Moreover, recent analysis of his hair has shown an almost 40-fold increase in arsenic concentration in comparison to normal people of that time. Several theories have been formulated, explaining how Napoleon Bonaparte could have been poisoned. Among the most curious being poisonous wallpaper, or the theory claiming that Napoleon was poisoned by a mixture of heavy metals (Hindmarsh and Corso, 1998). The first hypothesis builds on the fact that adding green arsenic-based pigment into wallpaper was quite common at that time. From a chemical point of view this pigment, called Paris Green, was copper(II) acetoarsenite. The humid weather of the island promoted the proliferation of microscopic fungi which could convert inorganic arsenic in Paris Green to an organic form. It is widely recognized that organic forms of heavy metals more easily cross the biological barriers compared to their corresponding inorganic salts. Therefore this theory assumes that Napoleon was intoxicated in particular by these organic forms of



FIGURE 1.13 French Emperor Napoleon Bonaparte (<https://thorvaldsensmuseum.dk/en/collections/work/E876/zoom>).

arsenic. The latter theory already assumes foreign blame. According to this hypothesis, low doses of arsenic were added to Napoleon’s food and drinks. The clinical picture of chronic intoxication with arsenic usually manifests as severe pain in the stomach. To relieve vomiting in Napoleon, the doctors administered him potassium tartarate of antimony. In addition to this remedy, his physicians prescribed him calomel and orgeat to combat constipation and thirst, which represent other characteristic symptoms of arsenic intoxication. The main component of orgeat is bitter almond oil, whereas calomel is a trivial name for mercury dichloride (Hg_2Cl_2). Hydrolyses of orgeat to hydrocyanic acid in the acidic gastric environment, together with calomel, gives rise to mercury cyanide. Therefore either arsenic, hydrocyanic acid, antimony, mercury cyanide, or a mixture of some or all of them could be one of the causes of Napoleon’s death (Mari et al., 2004).

1.4 The modern era

The Industrial Revolution in the middle of the 19th century allowed the synthesis of natural toxins in unlimited

quantity. Moreover, novel entities derived from natural compounds were prepared. Due to all the above-mentioned events, poisons were gradually losing their mystery (Nepovimova and Kuca, 2019). At the beginning of the 20th century, the development of toxicology was strongly influenced by progress in the chemical industry. From the perspective of chemical production, Germany was among the most developed countries. Within several branches of the chemical industry, German chemists even maintained a monopoly position, for example, in dye production. One of the most famous German chemists of the time was Fritz Haber (1868–1934) (Fig. 1.14), who discovered a method of ammonia synthesis from atmospheric nitrogen. Such an invention was of high importance for the large-scale synthesis of fertilizers and explosives. Therefore in 1918, Fritz Haber was awarded the Nobel Prize (Manchester, 2002). In the history of toxicology, F. Haber is better known for another reason, he is called the “Father of Chemical Weapons” due to his longlasting research in the field of weaponization of chlorine and other toxic gases in World War I (WWI). In addition, it was Haber’s suggestion to use chlorine in the first chemical attack by Germans against British/French troops on April 22, 1915, near the town of Ypres (Belgium) (Charles, 2005). Subsequently, the Allies (France, Great Britain, United States, and Russia) also started to use chemicals for military purposes. During the 4 years of WWI (1914–18), about 1.3 million people were affected



FIGURE 1.14 The “Father of Chemical Weapons” Fritz Haber (https://commons.wikimedia.org/wiki/File:Fritz_haber_1929_PI_29-C-0097.jpg).

by chemical weapons on both sides of the conflict, of which more than 100,000 died (Tucker, 2006).

On September 7, 1978, Bulgarian dissident Georgi Markov (1929–78), after an evening broadcast on the BBC, went around a crowded bus stop on the Waterloo Bridge in London and suddenly felt a slight sting in his leg. Looking around, the Bulgarian noticed a man picking up an umbrella from the ground. The stranger spoke with a strong accent, apologizing, and then caught a taxi and left. Due to a high fever, acute stomachache, and severe diarrhea, Markov was hospitalized that night, and a few days later he died. Fortunately, he managed to talk about the incident with the umbrella. Doctors, who performed an autopsy, found a small iridium-platinum capsule in the leg of the dissident. According to the findings of further investigations, this capsule with a diameter of less than 2 mm was filled with ricin (Crompton and Gall, 1980). Ricin is a plant toxin obtainable from the castor bean (*Ricinus communis*, *Euphorbiaceae*). By all accounts, Georgi Markov was shot by the Bulgarian special services because of his active criticism of the communist regime of Todor Zhivkov (Papaloucas et al., 2008). The killing device was an umbrella endowed with a hidden sting that shot small capsules filled with toxic ricin.

On March 20, 1995, the nerve agent sarin was used at several subway stations in Tokyo (Japan). About 10,000 people were affected, with 5000 seriously intoxicated and 12 people died. Sarin was used by the terrorists of the sect Aum Shinrikyo. They stored the nerve agent in plastic bags, which were subsequently punctured by an umbrella with a sharpened tip. The terrorists managed to puncture 10 of 11 bags. Fortunately, due to the low purity of the sarin (approximately 30%) and the subway ventilation system, the loss of life was not as high as it might have been (Okumura et al., 2005). The question that still needs to be answered is: “Why did the sect select sarin?” There are plenty of possibilities why: (1) inspiration from the Gulf War; (2) simple synthesis; (3) starting compounds availability; and (4) low production costs (Nozaki and Aikawa, 1995). Many sect members who participated in the sarin production process claimed that they were unaware of its toxic effects. However, the handbook “Magic song of sarin,” found in one of the buildings used by Aum Shinrikyo, apart from the instructions of how to synthesize the nerve agent, gave a description of its lethal effects. Therefore it was obvious that the members of the sect had lied (Kimura, 2002). The terrorist use of sarin in the Tokyo subway pointed out the serious risk of misuse of chemical warfare agents for nonmilitary purposes and highlighted the need for the development of appropriate protection including antidotal therapy.

The former President of Ukraine, Viktor Yushchenko (born 1954) (Fig. 1.15), was intoxicated by a very high dose of 2,3,7,8-tetrachlorodibenzodioxin (TCDD) in